
==== Front
Curr Neuropharmacol
Curr Neuropharmacol
CN
Current Neuropharmacology
1570-159X
1875-6190
Bentham Science Publishers

38073104
CN-22-1344
10.2174/1570159X22666231207114346
Medicine, Neurology, Pharmacology, Neuroscience
In Vitro Blood-Brain Barrier Models for Neuroinfectious Diseases: A Narrative Review
Badawi Ahmad Hussein 1
Mohamad Nur Afiqah 12
Stanslas Johnson 3
Kirby Brian Patrick 4
Neela Vasantha Kumari 5
Ramasamy Rajesh 6
Basri Hamidon 1*
1 Department of Neurology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia;
2 Centre for Foundation Studies, Lincoln University College, 47301, Petaling Jaya, Selangor, Malaysia;
3 Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia;
4 School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland;
5 Department of Medical Microbiology and Parasitology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia;
6 Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia
* Address correspondence to this author at the Department of Neurology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia; Tel: +603-9769 9266; E-mail: hamidon@upm.edu.my
08 12 2023
2024
22 8 13441373
12 9 2022
04 11 2022
25 11 2022
© 2024 The Author(s). Published by Bentham Science Publishers
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ © 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
The blood-brain barrier (BBB) is a complex, dynamic, and adaptable barrier between the peripheral blood system and the central nervous system. While this barrier protects the brain and spinal cord from inflammation and infection, it prevents most drugs from reaching the brain tissue. With the expanding interest in the pathophysiology of BBB, the development of in vitro BBB models has dramatically evolved. However, due to the lack of a standard model, a range of experimental protocols, BBB-phenotype markers, and permeability flux markers was utilized to construct in vitro BBB models. Several neuroinfectious diseases are associated with BBB dysfunction. To conduct neuroinfectious disease research effectively, there stems a need to design representative in vitro human BBB models that mimic the BBB's functional and molecular properties. The highest necessity is for an in vitro standardised BBB model that accurately represents all the complexities of an intact brain barrier. Thus, this in-depth review aims to describe the optimization and validation parameters for building BBB models and to discuss previous research on neuroinfectious diseases that have utilized in vitro BBB models. The findings in this review may serve as a basis for more efficient optimisation, validation, and maintenance of a structurally- and functionally intact BBB model, particularly for future studies on neuroinfectious diseases.

Keywords

Blood-brain barrier (BBB) model
standardization of BBB model
optimization parameters
validation parameters
neuroinfectious diseases
peripheral blood system
central nervous system
==== Body
pmc1 INTRODUCTION

The blood-brain barrier (BBB) is a selective structural and functional barrier that protects the central nervous system (CNS) from unrestricted access to molecules from circulating blood, which is required for the physiological functionality of glial cells and neurons. The BBB also stabilises the neural microenvironment by limiting the infiltration of the CNS and circulating neurotoxic agents, inflammatory factors, immune cells, or pathogens [1-4]. A disruption in the BBB may be due to the redistribution or degradation of tight junction proteins (TJP), causing enhanced BBB permeability [5, 6]. The recruitment of leukocytes into the brain is a prominent pathological feature in many neuroinfectious diseases,including cerebral infection [7] and multiple sclerosis [8]. This results in durable neurologic deficits and high mortality and morbidity rates globally [9].

Multidrug resistance proteins, such as P-glycoprotein, obstruct drug transport across the BBB that might promote the development of “sanctuary sites”, permitting pathogens to replicate in treated patients' brain tissue [10]. Despite advances in vaccines and antibiotic therapy, several microbial infections continue to be significant public health problems, resulting in a high rate of mortality and morbidity. Therefore, understanding the mechanisms by which pathogens penetrate the BBB is essential for future rapid diagnosis and treatment of neuroinfectious diseases. Animal models can contribute significantly to our understanding of the pathophysiology of neurodegenerative diseases. However, study findings through animal models have limited applicability to the human BBB as animal models have a higher transendothelial electrical resistance (TEER) value than human BBB models [11, 12]. There are also considerable species-specific differences in both animal and human BBB, including the timing of BBB maturation, clearance rates of amyloid-beta, different levels of expression and functions of BBB transporters, and differences in the activities of BBB metabolic enzyme [13]. Therefore, increased research on human BBB in vitro models has permitted a more detailed experimental study of the BBB, mechanical knowledge of the brain endothelium-pathogen interaction, an overview of human BBB pathophysiology, and leading to reduced dependence on animal models.

In this review, we present an overview of in vitro BBB models that are currently being utilised to study neuroinfectious diseases. We describe the various types of cells that compose the BBB, the factors that influence BBB permeability, the optimization and validation of parameters for a BBB model, and the applications of in vitro BBB models in previously published studies.

2 HUMAN BLOOD-BRAIN BARRIER CELLS AND BLOOD-BRAIN BARRIER PERMEABILITY

The BBB is a complex structure composed of diverse multicellular components that form a functional “neovascular unit”, which includes human brain endothelial cells that line the cerebral vasculature [14], capillary basement membrane, brain pericytes embedded within the basement membrane [15], and end-feet of brain astrocyte ensheathing the vessels [16-18].

Brain microvascular endothelial cells (BMECs) have specialised transport systems, a uniform thickness without transendothelial fenestrations, a low level of pinocytotic activity, continuous intercellular tight junctions, and a high mitochondrial volume [19, 20]. The existence of continuous tight and adherens junctions in the BMECs almost completely seals the paracellular space between adjacent lateral endothelial membranes [21-25].

Pericytes are critical capillary and post-capillary venule cellular constituents. They share the same basement membrane as endothelial cells [26] and cover 22-32% of capillaries in the CNS [27]. Pericytes are involved in various neurovascular functions, including angiogenesis, BBB formation during embryogenesis, vascular stability maintenance, capillary blood flow regulation, and eliminating toxic cellular products [28]. Pericytes can influence the production of tight junction molecules in endothelial cells via secreting factors, for instance, angiopoietin [29] and TGF-α [17]. TGF-improves BBB function by inhibiting leukocyte migration and endothelial cell proliferation. The release of angiopoietin can result in capillary remodelling and stabilisation. Endothelial cells secrete platelet-derived growth factor (PDGF), which is required to recruit and maintain pericytes on vessels and vascular maturation [30, 31].

Astrocytic end-feet cover 99% of the microvessel surface in the brain, with only a thin basal membrane separating their end-foot processes [18]. Astrocytes regulate numerous physiologic aspects of the BBB through the action of critical regulatory factors such as transforming growth factor-β (TGF-β) [17], glial-derived neurotrophic factor (GDNF) [32], and the fibroblast growth factor (FGF) [33]. Additionally, astrocytes affect specific BBB characteristics such as permeability, tight junction formation, and endothelial cell expression [34].

Neurons are typically 8-20 mm away from brain capillaries [35]. Neurons are also actively involved in forming BBB structure, as neuronal terminations are present in all BBB-forming cells [36, 37]. Neurons remain close to capillaries and link to astrocytic end-feet near the BBB. Due to their proximity to endothelial cells, neurons are able to respond to the constantly shifting local environment (e.g. ion balance). Neurons play a function in controlling blood flow, microvascular permeability, extracellular matrix interactions, and the release of substances that drive angiogenesis [38]. Signals from neurons and astrocytes can recruit microglia that produce proinflammatory cytokines in response to a vascular insult [39]. Neurons can induce and sustain BBB characteristics in vitro [40, 41]. Neurons contribute to the contraction of brain endothelial cells in culture by facilitating the synthesis and localization of tight junction proteins [41]. The production and function of BBB efflux transporters are regulated by neuronal activity, which is essential for excluding numerous tiny lipophilic compounds from the brain parenchyma. In addition, in brain endothelial cells, neuronal activity affects the expression of circadian clock genes, subsequently driving the activity-dependent regulation of BBB efflux transport [42]. These findings support a synergistic function for neuronal regulation of different cell types and emphasise the intercellular communication between these cells. Water channels within astrocytes connect the neural circuitry to the blood arteries [43].

Perivascular macrophages/microglia are the resident immune cells of the CNS. This cell holds a critical position in the BBB, allowing for the modulation of the brain's innate and adaptive immune responses. Human brain perivascular microglia express molecules implicated in antigen recognition, antigen presentation, and co-stimulation [44]. Therefore, microglia are an additional line of immune defence against infections or toxins that cross the BBB. Their function involves regulating BBB inflammation, maintaining endothelial cell health, stability and integrity of the BBB, regulation of vasoconstriction, and participation in angiogenesis and BBB recovery (TJP delivery) [45, 46]. Table 1 further summarises the characteristics and functions of human BBB cells.

Several factors and indicators determine the permeability of the BBB from inter-endothelial junctions, transporters and molecular markers. Adherens junctions induce endothelial cell adhesion, contact inhibition during vascular growth and remodelling, initiate cell polarity, and regulate paracellular permeability. Another inter-endothelial junction, the tight junction, acts as a physical barrier, forcing most molecules to cross the BBB via a transcellular pathway rather than a paracellular pathway. Both efflux and solute-like carrier (SLC) transporters are expressed on brain endothelial cells, which play crucial roles in the permeability of small molecules across the BBB. Their expression profile largely dictates their permeability properties and functions, which is a critical prerequisite for an in vitro BBB model [99, 100].

It is well established that the BBB is relatively impermeable under normal physiological conditions due to the presence of inter-endothelial junctions and transporters that regulate the pathways of substances. However, during pathologic conditions, multiple sources have been demonstrated to release chemical mediators, vasoactive agents, and cytokines/chemokines into tissues and the bloodstream, thereby disrupting the BBB’s permeability. Previous in vivo and in vitro studies have reported that several mediators, such as ATP, aspartate, glutamate, taurine, nitric oxide (NO), endothelin-1, TNF-α, and macrophage-inflammatory protein 2 (MIP2) produced by astrocytes, vasoactive agents (free radicals, 5HT, bradykinin, histamine, thrombin, substance P, quinolinic acid, UMP, UTP, and platelet-activating factor) and free radicals, interleukin-1 (IL-1) and interleukin-6 (IL-6) generated by bacterial protein lipopolysaccharide (LPS) could alter the BBB permeability [14, 47, 99-103].

Another significant regulator that affects the barrier’s permeability during inflammation is the vascular endothelial growth factor A (VEGFA) and thymidine phosphorylase (TYMP), which act synergistically to suppress the expression of occludin and claudin-5, which acts synergistically to suppress the occludin and claudin-5 expression, two transmembrane proteins required for the integrity of tight endothelial junctions [104, 105]. It has been demonstrated that the astrocyte-derived VEGFA is a significant contributor to barrier dysfunction via endothelial nitric oxide synthase (eNOS), which inhibits claudin-5 and occludin expression [106, 107]. Furthermore, along with the endothelial barrier antigen (EBA) and immunoglobulin G (IgG), VE-cadherin is a cell adhesion molecule expressed by the vascular endothelium [108]. It is mainly found at cellular junctions [109, 110] and is utilised as an indicator of the BBB’s loss of integrity [111]. Another factor that could play a significant role in disrupting the BBB’s permeability is the attenuation in caveolin-1 and MMPs levels [107, 112] since caveolin-1 is the caveolae's primary structural protein and may contribute to vesicular trafficking and cell signalling [113].

Several neuroinflammatory models [105] have reported the association of BBB permeability disruption with proinflammatory cytokines and chemokines response [114, 115]. For instance, The C-C motif chemokine ligand 2 (CCL2) disrupted the BBB barrier by binding to C-C chemokine receptor type 2 (CCR2) on the brain endothelium, thus disrupting the TJP [116, 117]. CCL2 is a crucial chemokine that mediates immune cell adhesion to the cerebral endothelium [118]. It is secreted by astrocytes and BMECs at the glia limitans, facilitating immune cell immunosurveillance activity within the BBB vasculature [119, 120].

3 IN VITRO BLOOD-BRAIN BARRIER MODEL

To accurately mimic a BBB condition, an in vitro BBB model must exhibit the same morphological, physical, and functional characteristics as the in vivo model. The BBB cells should be derived from human sources and preserved in a physiological and morphological environment consistent with that of the BBB. Co-culture of brain endothelial cells and other BBB cellular and structural components is recommended, and shear stress should be incorporated into the BBB model to mimic the in vivo blood flow. Additionally, the model should permit inflammatory cells to migrate transendothelial, which can be used to perform additional analyses such as cell counting, cellular markers, and viability. Finally, the model should allow for the incorporation of cytokines or chemokines to study their effect and role [121].

3.1 Types of in vitro Blood-brain Barrier Models

Many models of BBB have been proposed, including monoculture, co-cultures, triple cultures, quadruple cultures, and 3D ECM-based Transwell models and dynamic systems, including dynamic in vitro BBB model (DIV-BBB), microfluidic BBB (μBBB), and BBB-on-a-chip.

The benefits and drawbacks of these systems have been extensively explored in previous literature; thus, the advantages and disadvantages of different in vitro BBB models are summarized in Table 2. Validation markers, including the expression of BBB enzymes, transporters, receptors, and structural proteins, are utilised to generate overviews of the currently existing models for comparison and model selection [122-127].

3.2 Three-dimensional in vitro Blood-brain Barrier Models

Three-dimensional models (3D) are a crucial step forward in BBB modelling. Establishing the BBB in artificial microvessels is accomplished by the growth of BEC in the coated channels lumen to build a microstructure with the addition of perivascular cells (pericytes and astrocytes) on the outer surface of the channels [123]. In the specific example (3D ECM-based BBB models), brain microcapillaries are grown on self-polymerizing ECM scaffolds where the BBB cellular components can form tight contacts while being exposed to trophic nutrients along quasi-physiological biochemical gradients [124].

The advantage of the 3D model is: (a) the topographic distribution of BBB’s cellular component, which mimics the in vivo BBB, (b) the barrier characteristics resemble those in vivo more closely (transporter expression, cell polarization, and high TEER), and (c) a more realistic microcirculation environment comprising real-time monitoring, an oxygen permeable substrate, presence of shear stress and fluid flow, and biological measurement [123]. This design permits a more physiologically appropriate geometry and cell-cell interaction for investigating permeability and inflammatory response [128].

Due to the lack of flow and limited media exchange in two-dimensional (2D) models, the glucose consumption and lactate production of BEC are high [129]. This could convert the cellular metabolism to anaerobic metabolic pathways in pre-experimental circumstances and influence the phenotypic and pathological response of BEC.

Two-dimensional models are reproducible and cost-effective systems for drug transport and cell migration studies [130]. DIV-BBB offers a solid foundation for comprehending the influence of shear stress on BECs under diverse pathological states [130]. Potential applications of 3D models (μBBB, BBB-on-chip) include pharmacology (drug absorption, dosage, and drug development), disease-target research, and translational medicine [131].

3.3 Gold Standard or Ideal Model

There is currently no ideal or gold standard in vitro BBB model being developed due to a limited understanding of the human BBB, which makes determining the characteristics of an ideal in vitro BBB model challenging. On the other hand, an ideal model should meet several critical parameters, including the structural and functional features outlined in Table 3. The in vitro BBB model should be able to mimic the effects of different haemodynamic and immune/inflammatory insults on the BBB that may contribute to the aetiology and progression of CNS diseases [132].

A perfect in vitro BBB model should satisfy several essential criteria (Table 3). These include (a) enabling interendothelial tight junction expression between adjacent ECs, hence facilitating the creation of an extremely strict and selective BBB barrier (limited paracellular diffusion), (b) in vivo-like asymmetric-distribution (apical versus basolateral) of necessary transporters [133] which confers ECs polarisation, (c) the expression of functioning drug efflux and drug metabolism pathways [134-136], and (d) the capacity to distinguish the permeability of different substances [137].

The development of realistic in vitro BBB models that mimic the physiological and molecular properties of the NVU/BBB is crucial for CNS drug discovery, neuroinfectious research, and translational medicine. Successful modelling of the NVU would help dissect pathogenic causes and mechanisms of action (and targets) preceding the onset of CNS diseases. It is claimed that inadequate BBB model selection may affect data reliability and cause suboptimal clinical trial outcomes [122, 132].

3.3.1 Differences between Primary versus Immortalized Cell Lines of BBB and Animal versus Human-derived Cells

In previous work, animal cells rather than human cells were often used in in vitro models. Porcine or murine brain endothelium and rat astrocytes are employed in models because they are more accessible and economical to maintain, and well-characterized [138, 139]. These models are cultivated using an animal serum. How effectively can non-human models be extended to humans in vivo? Fully human models are needed to evaluate non-human models. Human brain-derived cells and other cell types cultured in serum-free environments, foetal bovine serum, and human serum show antigens and gene expression changes, which may cause junction tightening [140]. Animal and human serum can change cell morphology and tight junction development [141].

The differential expression of BBB transporters levels also indicates that there are some differences between the functions of the BBB in animals and humans [142-144]. P-gp expression differs between the rat and human models, presumably due to the fact that P-gp is encoded by two genes in rats but only one gene in humans [145]. Consequently, their regulation and protein expression may change.

Endothelial cells from diverse sources have been utilised to model in vitro BBB, including PSC-derived, primary and immortalised cells across various mammalian species. Primary BMECs are challenging to purify and rapidly lose their in vitro BBB phenotype [146], whereas immortalised BMECs are more convenient but frequently exhibit weak barrier functionality [147]. Other NVU cell types may have similar limitations due to their primary or immortalised cell sources, typically derived from animal tissues.

The cell type utilised is the most crucial aspect of any in vitro NVU/BBB model. This model's usability, cost-effectiveness, and translational relevance are all dependent on the cells utilised to build it in vitro since a more accurate representation of the physiological properties and response of the BBB can be achieved by this method. In addition, these cell types' availability and expandability can considerably impact the cost of operating and maintaining the platform [148].

Models of BBB derived from primary cells are the most accurate. Their relatively good correlations with in vivo models are typically associated with relatively high TEER values and low paracellular permeability of trace markers [149]. A disadvantage of these models is that the expression of transporter proteins and efflux pumps differs between species [126, 128], which has been proven to be a restrictive barrier of animal brain-derived primary endothelium cells in vitro [64, 150, 151]. Models employing primary cultures of human origin would eliminate species-specific differences; however, the availability of such cells is limited for ethical reasons.

The limitations of primary human cells include (a) primary cells are limited and often require a clinical equivalent from whom to extract brain tissue, (b) Time-consuming and low-yield [148], (c) primary cells are prone to contamination by NVU cell types such as astrocytes and pericytes, which can bring confounding variables such as altered cell monolayer layout and unintentional induction of BBB features to ECs [152], and (d) isolation and purification demand technical skills. Cells obtained from human brain tissue excision are likely related to the underlying brain disease. In vitro, these cells are more likely to have pathogenic features (such as drug resistance) [153, 154]. This is a benefit not afforded by cell lines or animal-derived primary cells; however, these cells are limited in availability [122], donor-to-donor variable, and disease-specific differences. Cell survival is a concern since primordial cells differentiate quickly in culture and dedifferentiate spontaneously after repeated passages. In vitro cell viability-carrying properties are also important, especially for human cells [122].

Due to these limitations, cerebral capillary endothelial cells have been immortalised with human telomerase reverse transcriptase catalytic subunit and Simian vacuolating virus 40 (hTERT/SV40) Large T antigen [147]. However, existing human brain capillary endothelial cell lines frequently exhibit defects, such as low TEER values, relatively high paracellular penetration of negative control substances, and inadequate expression of essential transporter systems [11]. Several factors, including cell types and co-culture media, should be considered when developing an optimal BBB in vitro model.

3.4 Optimization Factors of an in vitro Blood-brain Barrier Model

New cell culture support materials (anchoring/adhesive molecules), such as a matrix structure containing the desired anchoring or adhesive molecules (for cell adhesion or to elicit specific cellular responses), would allow researchers to more finely control cell differentiation, cellular interaction, and cellular response [132]. A larger surface area and the type of coated proteins, such as a fibronectin and collagen IV mixture coating, may significantly influence the endothelial basement membrane compared to a membrane/insert pre-coated with collagen. The culture period is also a factor that facilitates the proper formation of inter-endothelial adherents and tight junctions [155]. Other factors, such as initial cell loading, real-time monitoring of TEER values, and medium sampling, are also optimizable factors of an in vitro BBB model, which are further summarised in Table 4.

3.5 Validation of in vitro Blood-brain Barrier Model

Several methods of validating an in vitro BBB model are available. One frequently used technique is determining the TEER values arising from the cell-cell interaction of endothelial cells cultivated on a porous membrane. TEER is generally expressed as measured resistance (ohm) multiplied by the surface area of the endothelial monolayer (cm2). The membrane surface varies considerably and could have a value of 0.3 cm2 (24-well plate), 1 cm2 (12-well plate), and 4.2 cm2 (6-well plate). A higher TEER of the monolayer cells reflects a tighter barrier. Consequently, it is recommended to indicate the surface area of inserts in published studies [11]. Setting an ideal TEER value for a fully functional BBB model is challenging due to the wide variety of TEER values reported in numerous research studies using different models.

TEER values have been commonly used to evaluate the functionality of a BBB model in various species [156]. For instance, the TEER physiological resistance of the frog brain microvascular endothelium was reported to be greater than 1000 Ω.cm2 [157]. In contrast, the TEER of the BBB in rats was measured at 5900 Ω.cm2, which was considered relatively high compared to the available in vitro models [158]. The endothelial electrical resistance of the tight junctions between BBB endothelial cells in vivo ranges between 1500 Ω.cm2 and 2000 Ω.cm2 (pial vessels) [158, 159]. In light of this, endothelial cells are co-cultured with other brain cells in in vitro models to increase TEER values and replicate in vivo models [156].

The permeability of endothelial monolayer to tracer compounds with defined molecular weight, such as sodium fluorescein or fluorescein isothiocyanate (FITC)-dextran, Evans blue, and horseradish peroxidase, was recommended for the validation of an in vitro BBB model [180]. Monolayer cells need to be evaluated via uncharged solutes with differing sizes, which are highly inert and non-toxic and are not taken up by the cells. Choosing a range of tracers is essential in comprehensively evaluating monolayer integrity [181]. In general, because of the existence of tight junctions, the exogenous tracers would not be able to diffuse into the brain parenchyma unless the BBB permeability has been disrupted. As a result, they are a valuable tool for validating an in vitro BBB model [180].

Additionally, gene and protein expression analyses are performed to evaluate the structure and function of in vitro BBB models [182]. It is critical to investigate the changes in the expression of permeability-related genes because gaps in monolayer cells caused by improper handling or cell seeding, as well as changes in the ionic composition of the growth medium induced with specific treatments, could potentially lead to errors in the permeability measurement. Expression analyses also allow comparisons between the BBB integrity and gene expression of BBB-related proteins [183]. Improving in vitro BBB models is a principal challenge [182] and requires proper validation of various parameters, as summarised in Table 5. Meanwhile, the advantages and limitations of each method used to optimize and validate the in vitro BBB models are presented in Table 5.

3.6 Maintenance of in vitro Blood-brain Barrier Model

The features of the BBB are maintained by interactions between BBB cells (brain microvascular endothelial cells, pericytes, astrocytes, neurons, and microglia) [16, 196]. Abnormal interactions among these cells may interrupt the barrier function. Therefore, the maintenance of BBB structural and functional properties, including maintaining cell viability, constructing the tissue scaffold itself, monitoring cells for dedifferentiation after reaching complete differentiation, and confirmation of maintenance of BBB integrity, is required [162].

3.7 Designing Inflammatory in vitro Blood-brain Barrier Models

Neuroinflammatory substances are capable of impairing the tight junction integrity and efflux transporters, allowing the influx of immune cells, for instance, dendritic cells, neutrophils, and monocytes, as well as the secretion of proinflammatory cytokines into the CNS [197]. These cytokines will further affect astrocytes and endothelial cells by stimulating the expression of MMPs, adhesion molecules, chemokines, and cytokines, disrupting the BBB [198]. Moreover, cytokines serve as a chemoattractant for immune cells and induce signalling cascades that further upregulate their expression, resulting in neuroinflammation [199]. An inflammatory in vitro BBB model can be mimicked by integrating inflammatory mediators with BBB endothelial cells and including significant producers of inflammatory cytokines such as astrocytes, microglia, neurons, oligodendrocytes, monocytes, and neutrophils [200].

In a transfected human brain microvascular endothelial cells (THBMEC)-based in vitro BBB model, IL-1β upregulates the mRNA expression of intracellular adhesion molecule-1 (ICAM-1) more than TNF-α. IL-1β induces protein expression and the secretion of IL-1β, IL-6, IL-8, TNF-α, and MMP2, leading to TEER values decreasing by approximately 35% and increasing paracellular permeability. IL-1β also significantly increases the number of transmigrated peripheral blood mononuclear cells (PBMCs), T-lymphocytes, and monocytes by 50%. TNF-α treatment, on the other hand, did not affect the THBMEC layer [172]. Comparatively, the cytokines and chemokines of NT2 human astrocytes mediate human leukocytes (monocytes, NK cells, B cells and T cells) migration by more than 500% [201].

Shigemoto-Mogami et al. reported that a rat in vitro BBB model (RBT-24H), comprising endothelial cells, pericytes, and astrocytes, incubated for one day with LPS-activated microglia (LPS-MG) to the basolateral side, had a significantly reduced TEER value and increased paracellular transport of sodium fluorescein [202]. The expression levels of occludin and ZO-1 were significantly reduced, indicating that microglial activation could prompt BBB disruption during neuroinflammation. The concentrations of 19 cytokines/chemokines were significantly increased by LPS-MG including GRO/KC, LIX, IP-10, MIP-1α, MIP-2, MCP-1, RANTES, fractalkine, leptin, IL-1α, IL-1β, IL-4, IL-5, IL-6, IL-10, IL-12 (p70), IL-13, TNF-α, and IFN-γ in the in vitro model. However, different co-cultures revealed contradictory results, indicating that the effect of cytokines/chemokines is influenced by the interactions between microglia and astrocytes rather than by activated microglia alone [202]. In contrast, Banks et al. discovered no significant influence of microglia, astrocytes, or pericytes on the BBB disruption induced by LPS [203]. An in vitro model by Burkert et al. reported that GM-CSF, IL-1β, IL-6, IL-8, IL-13, TNFα, MCP-1, MIP-1, and IP-10 were secreted from human NT2 astrocytes following proinflammatory activation (IL-1β and TNFα stimulation), and IL-6, IL-8, GM-CSF, MIP-1α and IL-13 were produced post-activation (by phorbol 12-myristate 13-acetate (PMA)). However, other cytokines, namely IL-2, IL-4, IL-5, IL-7, IL-12, IL-21, IFNc, LTa, and Fas ligand, were not detected under any stimulation condition [201].

In a primary mouse brain microvascular endothelial cell (pMBMEC) in vitro BBB model, the endothelial cell surface levels of recombinant murine ICAM-1 determined the cellular pathway of CD4+ TEM-cell (encephalitogenic CD4+ TH1 effector/memory proteolipid protein (PLP) peptide aa139-153-specific T-cell line SJL.PLP7) and caused extravasation across the in vitro inflamed barrier [204]. It was revealed that the CD4+ TEM cells primarily crossed the recombinant murine TNF-α-stimulated VE-CadGFP and IL-1β (0.05 ng/mL)-stimulated VE-CadGFP of pMBMEC monolayer paracellularly, whereas 52% migrated trans across the IL-1β (20 ng/mL)-stimulated pMBMEC monolayer. Therefore, this study demonstrated that endothelial ICAM-1 level on the cell surface influenced the pathway of T-cell extravasation through the BBB rather than the BBB integrity or an inflammatory stimulant [205].

In a human umbilical vein endothelial cell astrocyte-conditioned medium (HUVEC-ACM) in vitro BBB model, the ability of human neutrophils and monocytes to transmigrate (characterised as rate and extent of transmigration) across the endothelium was unaffected by the tightness of the endothelial BBB under non-activated and TNF-activated conditions [9]. Similarly, this was observed in transmigration across human brain TY10 and hCMEC/D3 cell lines. Disrupting the function of PECAM-1 and CD99 (via blocking mAbs) significantly reduced diapedesis to 20% and 15%, respectively. It was established that monocytes are predominantly paracellular (> 98%) rather than transcellular, transmigrating near the TJs. Transmigration showed no significant increase in TEER and FITC-dextran permeability [9].

Winger et al. also demonstrated that diapedesis followed a similar pathway in high-TEER BBB endothelium and conventional endothelium, with gap formation in VE-cadherin distribution. Claudin-5 and VE-cadherin gaps were modified after the diapedesis completion of monocytes. These findings established that diapedesis is a tightly controlled process, providing a new understanding of endothelial-leukocyte interaction at the barrier and implying that TJs are more dynamic than previously recognised [9].

4 IN VITRO BLOOD-BRAIN BARRIER MODEL IN STUDIES OF NEUROINFECTIOUS DISEASES

Experimental cell culture models are required to understand the pathophysiology of the BBB and to investigate the trafficking of parasites, viruses, fungi, bacteria, immune cells, or drugs into the CNS, which will eventually result in the establishment of protective and therapeutic methods to inhibit microorganism access or penetration across the BBB. The migration of trans-endothelial leukocytes across an impaired brain microvasculature is a noted feature of many neuroinflammatory diseases. It is ambiguous whether the immune cells cross the BBB via TJs, a vacuole, a large pore, or other mechanisms [204]. The in vitro BBB model has been applied to study the pathophysiology of many inflammatory and infectious neurological diseases, including meningitis, multiple sclerosis, and neurocysticercosis, but with varying results. The impact of the selected diseases on BBB parameters is illustrated in Fig. (1). The in vitro BBB model applications in neuroinfectious diseases studies, which are discussed in this section, are summarized in Table 6.

4.1 Bacterial Infection

4.1.1 Escherichia coli Meningitis

Disruption of the BBB is widely regarded as a hallmark of the pathogenesis of bacterial meningitis but with an unknown mechanism [9]. Escherichia coli (E. coli) meningitis was hypothesised to occur because of a bacterial invasion of the barrier, which leads to the development of CNS infection [206].

In a human hBMECs in vitro BBB model, the meningitic E. coli PCN033 strain (at the multiplicity of infection (MOI)=10, ~ 108 colony-forming units (CFUs)) significantly upregulated the transcription of platelet-derived growth factor-B (PDGF-B) and ICAM-1, which reduces any accompanying infection [207]. PDGF-B reduced the TEER values of the hBMEC monolayer and downregulated the mRNA levels of TJP expression, including ZO-1, occluding, and claudin-5 [207]. Apart from PDGF-B, the meningitic E. coli PCN033 strain also showed evidence of enhanced Snail-1 and VEGFA upregulation via TLR2-MAPK-ERK1/2 signalling pathway in an in vitro hBMEC monolayer and mice models [105]. Similar to PDGF-B, the expression of Snail-1 and VEGFA also downregulates the expression of TJP, leading to an increase in the permeability of BBB. Meningitic E. coli infection resulted in a significant secretion of GRO-α, MIP-2, MCP-1, IL-1β, IL-6, and TNF-α, which also enhanced the upregulation of Snail-1 and VEGFA, further accelerating the BBB damage. These findings demonstrated the involvement of ICAM-1 and PDGF-B in bacteria-induced BBB disruption and neuroinflammation, indicating that they could contribute to the prevention and treatment of bacterial meningitis [207], whereas Snail-1 and VEGFA serve as critical targets for meningitic E. coli, which eventually induced CNS destruction [105].

Another meningitic E. coli strain (RS218 (O18:K1:H7)) with specific virulence factors (NlpI, OmpA and FimH) was reported to upregulate the expression and release of heparin-binding epidermal growth factor-like ligand (HB-EGF) in an in vitro model. The HB-EGF then lead to epidermal growth factor receptor (EGFR) transactivation, which depends on the sphingosine kinases 2 (SphK2)-sphingosine 1-phosphate (S1P) (SphK2-S1P-S1P2) signalling cascade. However, the underlying mechanisms are still ambiguous [208].

4.1.2 Pneumococcal meningitis

Two clinical strains of Streptococcus pneumoniae (S. pneumonia) serotype 19F (RSP1 isolated from gastric infection and RSP2 from an ear infection) demonstrated increased adherence and invasion (MOI=1) abilities in an in vitro bEnd.3 model compared to the control strain. Researchers determined that the S. pneumoniae strains isolated from the ear and gastric infection sites can cause severe secondary infections, such as bacterial meningitis [184]. No difference in VE-cadherin staining was observed in HBMEC after incubation with S. pneumoniae TIGR4 (106 CFU) for an hour. Homogenous expression of VE-cadherin was observed at intercellular junctions in the juxtaposition of attached pneumococci, implying that the interaction between S. pneumoniae and the BBB does not result in a significant disruption of endothelial integrity [209]. The 37/67-kDa (kilodalton) laminin receptor (LR) was recognised as a common receptor for Haemophilus influenza (H. Influenza), S. pneumoniae and Neisseria meningitides on the surface of the mouse and human BMECs in both in vivo and in vitro studies. It is likely that inflammation during the bacteremia preceding the onset of meningitis plays a crucial role in upregulating LR prior to the LR-bacteria interaction. Furthermore, mutagenesis studies revealed that the correlated bacterial LR-binding adhesins were OmpP2 of H. influenzae, pneumococcal CbpA, meningococcal PorA (Porin protein), and PilQ (Pilin accessory protein). This interaction could facilitate infection transmission throughout the body since LR is commonly expressed in cell types in the human organs [210].

4.1.3 Streptococcal meningitis (Neonatal Meningitis)

It was discovered that Group B Streptococcus (GBS) COH1 binds to both the cell surface and immobilised fibronectin, a critical ECM component of the barrier and a ligand for the β1-integrin family [211], forming a streptococcal fibronectin-binding protein A (SfbA). The SfbA expression in the non-invasive strain of Lactococcus lactis was adequate to enhance the binding of fibronectin and the invasion of hBMEC. Furthermore, inhibiting fibronectin binding to integrins with an anti-fibronectin antibody caused a significant reduction of the invasion of the wild-type strain but not the SfbA-deficient mutant strain, indicating that the interaction of SfbA-fibronectin-integrin is required for cellular invasion of GBS (MOI=1 and 10). Another study showed that wild-type GBS adhered to, invaded, and stimulated induced pluripotent stem cells (iPSC)-derived BMECs and exacerbated the disruption of the tight junction proteins, whilst mutant GBS, with impaired interaction, was attenuated in the iPSC-derived BMEC model [212]. These findings indicate that GBS-SfbA has a crucial contribution to the interaction between BBB endothelium and GBS and streptococcal meningitis pathogenesis [213].

4.2 Viral Infection

Viruses are silent reservoirs within the body that have the potential for tissue destruction. A CNS infection presents a particular challenge due to the strict control of the BBB. Neuroinvasive viruses that can cross the BBB include tick-borne encephalitis virus (TBEV), Japanese encephalitis virus (JEV), and West Nile virus (WNV). Although the molecular determinants underlying the neuroinvasive phenotype remain unknown, the Visna virus and HIV have shown evidence of crossing the CNS intracellularly by invading infected cells [214].

4.2.1 Coronavirus Disease (COVID-19)-associated Neurological Disease

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects humans via the widely expressed angiotensin-converting enzyme 2 (ACE2) receptor [215, 216], which is found on a diversity of cells, for instance, alveolar type-2 cells, glial cells, brain endothelial cells, and neurons [217-221]. Human BMVECs have also been shown to express the ACE2 and NRP1 receptors [218, 220], making them possible targets for SARS-CoV-2 infection [220]. SARS-CoV-2 could infect the CNS due to the presence of virus entry receptors (ACE2, NRP1, and BSG) and viral modification (TMPRSS2, CTSL, and others) in the human brain [221].

An early in vitro study of the coronavirus JHM OMP1 strain revealed that it was capable of infecting cultivated BMVECs from rhesus macaques and humans [222], implying that the virus could cross the BBB. A more recent study discovered that the human umbilical vein endothelial cells (HUVEC) had a high level of ACE2 expression. The S1 subunit of the SARS-CoV-2 spike protein (11.1%) was present in the HUVEC cells and endocytosed HUVEC cells, which co-localised with caspase 3 (the isolated spike and isolated caspase 3). Increased HUVEC adhesion and degeneration and a significant increase of spike subunit and caspase 3 cells (in percentage) were observed in increasing the S1 spike protein concentration (70 ng/ml to 350 ng/ml) [223].

Immunofluorescence labelling revealed that after a SARS-CoV-2 spike protein administration, basal ACE2 receptor expression was dramatically elevated in BMVEC. Researchers discovered that the primary human BMVEC express ACE2 receptors as exposure to SARS-CoV-2 spike protein increases [224]. Using the ohmmeter Millicell ERS system, a significant drop in TEER was seen in a 2D BBB in vitro co-culture Transwell model treated with SARS-CoV-2 spike protein (0.5 g/ml) with a 29% decrease in TEER and or heat-inactivated SARS-COV-2 (5 μl/ml medium) with a 30% decrease in TEER value. These findings imply that SARS-CoV-2 exposure changes BBB integrity, allowing neuroinvasion [224]. Furthermore, gene expression levels analysed by real-time quantitative PCR reported TJPs JAM-2 (45%), ZO-1 (52%), ZO-2 (92%), and claudin-5 (97%) to be significantly lower in recombinant SARS-CoV-2 spike protein-treated BMVEC, compared to JAM-2 (85%), ZO-1 (69%), ZO-2 (86%), and claudin-5 (95%), heat-inactivated SARS-CoV-2 spike protein-treated. This showed that SARS-CoV-2 could alter gene expression of TJP and or post-translational modifications, hence impairing the integrity and function of the BBB. TNF-, IL-6, IL-10, IL-23, and IL-33 production were also found to be significantly increased, indicating a considerable rise in pro-inflammatory cytokines that, through the ACE2 receptor, would trigger endothelial inflammation and compromise the BBB’s integrity in BMVEC cells, thereby allowing SARS-CoV-2 neuroinvasion [224]. Therefore, findings from this study revealed that SARS-CoV-2 might penetrate the BBB through non-specific endocytosis or spike protein-ACE2 interactions, resulting in neuroinflammatory reactions and neuropathology [224].

ACE2 was expressed in primary hBMVECs and hCMEC/D3 cells in another study. However, in these cells, the spike protein subunits (subunit S1 or S2) had no effect on ACE2 expression. Only chronic exposure to the SARS-CoV-2 spike protein (> 72 h) resulted in a significantly higher rate of cell death [225]. These results corroborated recent clinical evidence indicating endothelial cell loss in severe infections of COVID-19 [225].

The spike protein subunits caused a dose-dependent decrease in the electrical resistance of the hBMVECs' barrier, which peaked at 12-14 hours (using ECIS). Both the SARS-CoV-2 subunits S1 and S2 induced comparable effects in addition to a temporary reduction of electrical resistance that was regained entirely after 24 hours, suggesting that structural reconfiguration occurred rather than an evident loss of tight junctional complex. The rate of passive paracellular penetration of small tracer molecules (4 kDa FITC-dextran) significantly increased with each additional SARS-CoV-2 spike protein subunit, providing another signal of barrier disruption. The SARS-CoV-2 spike protein is believed to have the ability to generate a low-grade chronic disruption of BBB that is time and concentration-dependent. Increased barrier permeability and decreased ZO-1 localisation to cell-cell junctions in a 3D human BBB model confirm the results of the 2D BBB model, suggesting that the subunit S1 of SARS-CoV-2 is responsible for BBB failure [226].

The fact that S1 and S2 subunits and receptor-binding domain (RBD) have similar impacts on barrier function is intriguing because it indicates that the SARS-CoV-2 - brain endothelial cells interaction is complex and not dependent on ACE2 receptor alone. The SARS-CoV-2 -BBB interaction is most likely multifocal, including reversible activation of several receptors or signalling pathways [226]. Moreover, the increased ECM enzymes (MMP3), cell adhesion molecules (ICAM-1 and VCAM-1) and endothelial pro-inflammatory response (CCL5, CXCL10) in the human endothelial cells further suggest that SARS-CoV-2 is possibly a neuroinvasive virus since it activates the mechanism that facilitates the migration of infected immune cells into the brain parenchyma as “Trojan horses” [226].

SARS-CoV-2 could induce neuroinflammatory responses without any virus entering the target cell cytoplasm, as the virus degradation in the lysosome or endosome can activate danger-associated molecular patterns (DAMPs) and or pathogen-associated molecular patterns (PAMPs) to induce immune response [227]. Coronaviruses may also reach the CNS through a compromised BBB caused by intracellular virus transmigration of macrophages, inflammatory mediators, brain endothelial damage or endothelitis, or direct infection of brain endothelial cells [228-231].

4.2.2 Human Immunodeficiency Virus (HIV-1)-associated Neurocognitive Disorder

Despite the development of potent antiretroviral therapy, human immunodeficiency virus-associated neurocognitive disorders (HAND) continue to be among the mainly frequent disorders presented in HIV-infected individuals. HAND refers to a severe form of CNS association, including asymptomatic neurocognitive impairment (ANI), minor neurocognitive disorder (MND), and more severe HIV-associated dementia (HAD) [232]. HAND is frequently linked to HIV morbidity, including the presence of a ‘hidden epidemic’ in the CNS [233].

A study from McFarren et al. showed that 213Bi-2556 mAb (Human IgG1 mAb 2556 to gp41) could cross a human BMVEC-astrocytes in vitro BBB model via transcytosis and mainly kill transmigrated HIV-infected PBMCs and monocytes (CD14+CD16+ cells) without apparent disruption of the BBB [234]. In a human BMVEC-brain pericytes co-culture model with monocyte adhesion/migration, it was discovered that there was reduced expression of Cx43, α-smooth muscle actin (a-SMA), α1-integrin, and platelet-derived growth factor-B receptor (PDGF-Rβ) (pericytes markers) [235]. This was followed by the increased number of filopodia after exposure to TNF-α or IL-1β, indicating the development of a migratory phenotype that has less coverage of the barrier. Pericytes stimulation by pro-inflammatory cytokines (IL-1β and TNF-α) associated with HIV neuropathogenesis and HIV-1 led to an increase in inflammatory factor secretion, adhesion molecules upregulation, and a migratory phenotype, altogether possibly promoting to the disruption of BBB [235].

Furthermore, assessed alteration in mRNA expression of basement membrane components, fibronectin, and nidogen showed a downregulation (60%) in stimulated pericytes and a significant reduction (25%) in metalloproteinases-3 (TIMP3), a tissue inhibitor. These results imply possible pericyte dysfunction, including the expression of cellular markers and receptors and the production of BBB-supporting factors, which may contribute to BBB disruption. A significant increase (7-8% high) in the TEER of BMVEC-pericyte cultures was observed post-incubation with primary human monocytes. Monocyte migration to the abluminal of BMVEC was increased 6-7-fold when BMVEC and pericytes were co-cultured following CCL2 addition, a cytokine upregulated in HIV-1 infection of the CNS [236], showing increased BBB “tightness” in a co-culture with pericytes. Pericytes stimulation with TNF-α increased upregulation of ICAM-1 (7-10-fold) and vascular cell adhesion molecule-1 (VCAM-1) (4-7-fold) expression. These findings indicated that pericytes might play a role in monocyte penetration across the barrier and retention in perivascular spaces [235].

4.2.3 Viral Encephalitis

Viral encephalitis is the inflammation and swelling of the brain, which can be caused by enteroviruses, adenovirus, Epstein-Barr virus, Japanese encephalitis virus, and many more [237]. In HBEC-5i cells-primary astrocytes in vitro BBB model, infection by Semliki Forest virus (SFV6) and SFV6-162K strains (MOI=0.1) caused a significant decrease in TEER. The capability of SFV to cross the in vitro BBB is related to its ability to replicate in the brain, but not the capability to produce a high-titre viremia [214].

It was also reported that glutamic acid elevates the viral load in mouse blood plasma, neuroinvasion and virulence. Lysine promotes the capability of the virus to traverse the BBB and replicate in the brain. Viruses with the dominant dependence on binding to glycosaminoglycans (GAGs) replicate to higher titres in the brain and can traverse the in vitro BBB [214].

In another HBEC-astrocytes in vitro BBB model, Japanese encephalitis virus (JEV) strain CNS138-11 could infect (MOI=1) both HBECs and astrocytes and elevate BBB permeability (approximately mean TEER 100 to 50) with limited active viral production in endothelial cells before traversing the barrier and infecting astrocytes. This enhanced permeability has been interpreted as a further viral entry pathway into the CNS. HBECs act as the initial barrier to JEV transmigration. JEV may infect and replicate HBECs prior to infiltrating the brain and stimulating a robust pro-inflammatory response in HBECs and astrocytes [13].

The release of CCL5, CXCL10, and IL-6 upon JEV infection elevated with time and was associated with TEER. Numerous factors, including CXCL10, MMP7, VCAM, leptin, and IL-6, showed significant correlations with TEER. However, releasing these factors may exacerbate BBB disruption and provide an entry point for the JEV to cross into the brain [13].

Comparatively, in an HBMVE in vitro BBB model, WNV (strain NY99), infection (MOI=1 and 5) in HBMVE cells did not cause a gross cytopathic effect. However, elevated expressions of mRNA and protein of claudin-1, VCAM, and E-selectin were observed post-infection. The cell-free penetration of WNV through the barrier via the transcellular pathway, rather than the paracellular pathway, did not compromise the BBB integrity, and post-infection TEER values and FITC-dextran percentage did not differ significantly. This could be due to the possibility that WNV-infected HBMVE cells help the virus enter via the ‘Trojan horse’ mechanism, in which infected monocytes or macrophages travel into the CNS and transmit WNV into brain cells [238].

Another HBMVE-HBCA in vitro BBB model proved that WNV strain NY99 could efficiently replicate in HBMVE cells [6]. WNV infection is vulnerable to human brain cortical astrocytes (HBCA) (MOI=5), whereby WNV promoted mRNA and protein expression of MMP-1, -3, -9 in HBCA cells (MOI=5 and 3). It was strongly suggested that virus replication and virus entrance triggers MMP production. ZO-1 protein decrease was observed in HBMVE cells treated with the WNV-infected HBCA cells' supernatant and increased expression of claudin-1. In the presence of an MMP inhibitor, the integrity of the BBB model damaged by MMPs released by WNV-infected HBCA cells can be restored. BBB models incubated with the WNV-infected HBCA cells' supernatant had their TEER decreased significantly (from 650 Ω/cm2 to ~400 Ω/cm2), while their FITC-dextran transmigration increased significantly (from 2%-3% to 190%). These findings suggested that the brain astrocytes produce MMP, which causes BBB breakdown, allowing immune cells unlimited access to the brain and leading to WNV-neuropathogenesis [6].

4.2.4 Dengue Virus Infection

The cerebrovascular endothelium’s involvement and the alteration of the BBB associated with neurological symptoms following dengue virus infection and dissemination in the CNS are unknown [239]. Only one study in a neonatal mouse brain endothelial cells (MBECs) and MBECs-astrocytes in vitro BBB model showed that they are susceptible to infection by both DENV-4 and D4MB-6 variants (MOI=1) and are characterised by perinuclear-localized viral E protein [239].

A disruption in the endothelial barrier permits paracellular transport of the dengue virus. These findings demonstrate that the early stages of infection (transcription-translation of viral proteins and viral entrance) resulted in significant alterations to the BBB functioning, allowing the transcellular or paracellular transport of free viruses from the apical to the basolateral of the filter support [239].

Both virus DENV-4 and D4MB-6 strain infections cause a significant increase in blue dextran concentration (30% in DENV-4-infected cells and 60% in D4MB-6-infected cells), concurring with the changes in TEER (34% in DENV-4-infected cells and 44% in D4MB-6-infected cells). TEER loss (18.1% in DENV-4- and 16.3% in D4MB-6-infected cells) is less severe and resulted in a slight increase in blue dextran concentration (less than 1%) in the MBECs-astrocytes co-culture model. These findings reveal that astrocytes play a protective role in brain endothelial responses during a dengue virus neuro-infection [239].

Dengue virus infection also prompts alterations in the subcellular-localized ZO-1 and Claudine-1. A DENV-4 infection has no effect on the MBEC cells with a ZO-1 pattern and in both BBB models. In contrast, the D4MB-6 virus influences the re-localization of ZO-1 from the cell border to the cytoplasm, causing an interrupted linear fluorescence pattern in the membrane. Although both viruses promote detachment of cells, the monolayer model of MBEC was reported to be extended effective in terms of cell loss and complete ZO-1 re-arrangement [239].

Furthermore, D4MB-6 infection promotes brain endothelial activation and monocytes/macrophages transmigration. D4MB-6-infected endothelial cells in the MBEC-astrocyte co-culture model permitted significantly higher migration of J774 macrophages, even when these macrophages were not infected. It is suggested that a Trojan horse mechanism is exploited late in the infection stage. This mechanism, together with viral paracellular transport, is the primary strategy for the dengue virus to gain entry into the CNS [239].

4.2.5 Zika Virus Infection

Zika virus (ZIKV), a mosquito-borne flavivirus, is neurotropic in infants [240] and adults [241]. In an in vitro BBB model derived from human iPSCs, it was demonstrated that ZIKV isolate 2013 (i.e., Asian lineage) could cross the in vitro barrier through the iPSC-derived induced brain endothelial cell (i-BEC), induced neural progenitor cells (i-NP), and i-Ns, and thus infect neural cells [186].

The ZIKV (MOI=4) can cross the human intact BBB model (via measuring ZO-1, TEER ≥ 300 Ω.cm2) without affecting its sodium fluorescein permeability paracellular nor the i-BEC monolayer viability. AXL, a well-characterised ZIKV entry receptor, is overexpressed in i-BEC and i-NPs with ZIKV susceptibility. Thus, the primary mechanism by which ZIKV crosses the BBB has been hypothesised to involve infection of i-BEC, transcellular crossing, and release onto the monolayer’s abluminal surface [186].

4.2.6 Hepatitis C Virus Infection-associated Neuropathology

Hepatitis C virus (HCV) is primarily a hepatotropic virus that could result in a range of extrahepatic conditions, including CNS disorders and progressive liver disease [242]. HBECs facilitate the entry and replication of HCV (HCV envelope glycoproteins (HCVpp) and vesicular stomatitis virus G glycoprotein (VSV-Gpp)) in an in vitro BBB model elucidating a possible pathway for an HCV infection of the CNS. All crucial HCV receptors are expressed on hCMEC/ D3 and HBMEC [243], facilitating the entrance of HCVpp.

Antibodies of SR-BI, CD81, claudin-1, and E2 glycoprotein dramatically inhibited infection of hCMEC/D3 cells, demonstrating that cellular CD81 and virus-associated ApoE have a role in the transmission of virus between HBECs, and a receptor-dependent entry route similar to that found in hepatocytes and cell lines derived from hepatocellular carcinoma [243, 244]. Infection of hCMEC/D3 results in increasing HCV RNA and antigen expression gradually, resulting in cytopathic effect and increased paracellular permeability marker fluorescein isothiocyanate/dextran 70 kDa, hence demonstrating that HCV has the potential to compromise the integrity of brain endothelial cells. This is further proved when HCV infection is neutralised by anti-HCV patient immunoglobulin pooled, restoring hCMEC/D3 permeability and suggesting a direct effect of infection [245].

4.3 Parasitic Infection

In vitro BBB models allow for direct research and utilization of the molecular pathways behind African trypanosome transmigration into the brain. It was demonstrated that two human pathogenic strains (Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense) and T. b. brucei TC221 could traverse the optimised ECV304-C6 BBB. These findings indicated that the J774 macrophage transmigration had no synergistic effect on T. b. brucei TC221 traversal. A tenfold (106 to 107 parasites/insert) increased trypanosomal inoculum resulted in an increase in T.b. brucei and T.b. rhodesiense transmigration but not in T.b. gambiense transmigration, showing that a particular density of trypanosomes is requisite to be reached to achieve the highest rate of transmigration. This study demonstrated that parasites traversed an inverse ECV304-C6 BBB model with comparable transmigration rates to the conventional BBB model [246].

4.3.1 Cerebral malaria

Cerebral malaria (CM) is a severe infection caused by Plasmodium falciparum. In in vitro endothelial Plasmodium berghei ANKA (PbA) cross-presentation model, primary MBECs activated with IFNγ were destroyed by infected mouse CD8+ T lymphocytes when grown with parasite-infected red blood cells [247]. No cross-presentation was observed when PbA mature stages (merozoites) were isolated from MBECs using Transwell inserts, indicating that the cross-presented antigen source was not a soluble protein. PbA were phagocytosed and cross-presented more effectively than parasite strains without resulting in in vitro CM, inferring that free merozoites were probably the primary source of cross-presented antigen [247]. The mouse brain endothelial cells primarily phagocytosed digestive vacuoles and free merozoites. Immortalised hCMEC/D3 cells phagocytosed merozoites with high avidity, implying that brain endothelial cells' cross-presentation of parasite antigens may contribute to the human CM pathogenesis [247].

In a co-culture of Plasmodium falciparum RAOL isolate-parasitised human red blood cells (PRBCs) and hCMEC/D3 cells model, cytoadherence of PRBCs was mediated by a trypsin-sensitive antigen (60% parasitaemia and 2.5% haematocrit), as trypsin treatment significantly reduced PRBCs' capacity to attach to endothelial cells. These findings suggested that cytoadherence was mediated by a trypsin-sensitive antigen expressed by P. falciparum RAOL as well as hICAM-1 expressed by (TNFα)-stimulated hCMEC/D3 cells [248]. Furthermore, PRBCs (50% parasitaemia and 2.5% haematocrit) and merozoites demonstrated the ZO1 disorganization immunostaining with spaces between cells and ZO1 relocalisation in the intracellular compartment of the hCMEC/D3 co-culture. A higher dose of the parasite (8 x 107 parasites/cm2) significantly increased the permeability of endothelial cells in this model, and PRBCs-induced permeability of endothelial cell alteration showed contact-independent and cytoadherence mechanism through the decrease of the environmental pH of the culture (acidosis) [248].

4.4 Neurocysticercosis

Secretory and excretory antigens of Taenia solium cysticerci cause angiogenesis in an in vitro HUVEC model by endothelial cell tube formation assay [108]. The in vitro HUVEC model supports the theory that angiogenesis in neurocysticercosis (NCC) is generated by the parasite rather than the host's inflammatory reactions. Upon infection, there was the presence of brain vascular changes, BBB disruption (EBA and IgG), overexpression of angiogenesis markers (VEGF-A and FGF2), and surrounding viable cysts. Vessels revealed EBA marker reduced immunoreactivity and widespread IgG staining in the tissues around the cysts. In astrocytes, VEGF-A expression was increased, reflecting the possible involvement of astrocytes in the pathogenesis of NCC [108].

A study by Lachenmaier et al. applied an in vitro rat brain endothelial and glial cells BBB model to investigate the possibility of Toxoplasma gondii (T. gondii) migrating intracellularly rather than extracellularly through the BBB in a ‘Trojan horse’ mechanism. Regulated genes related to cell adhesion (E-selectin, P-selectin and ICAM-1), toll-like receptor (TLR) 4, tight junctions, cytokines (IL-6) and chemokines (CCL2 (MCP-1), CCL7 and CX3CL1) suggest that the neuroinvasion of T. gondi) GFP+ tachyzoites RH strain (type I) and ME49 strain (type II) in bEnd. 3 cells may involve the utilization of leukocyte transendothelial migration pathways. Additionally, the infected CD45+/CD11bc+ (antigen-presenting) cells percentage significantly increased to 4.63% after migration compared to 0.6% of infected CD45+/ CD11bc− (lymphocytes) cells. Therefore, T. gondii was likely to be transported across the barrier through these antigen-presenting cells [249].

The CD11b+ cells were also the predominant cells migrating through the barrier upon infection with GFP+ tachyzoites (MOI=1) with upregulation of ICAM-1, enabling the leukocyte migration across endothelial barriers in the rat in vitro BBB model [249]. Meanwhile, compared to the RH strain (type I) tachyzoites, the ME49 strain (type II) showed significant early infectivity post-infection in bEnd.3 cells simultaneously stimulated the ICAM-1 overexpression and IL-6 and MCP-1 high secretion. Tachyzoites of the ME49 strain tended to infect more CD11b, CD11c, or both cells prior to migration, implying that Toxoplasma strains type I or type II would produce similar migratory cell patterns through the in vitro BBB [249].

5 OTHER APPLICATIONS OF IN VITRO BLOOD-BRAIN BARRIER MODEL

In vitro, BBB models have several applications for studying the BBB's structure and function in health and diseases, drug research, and toxicology, including facilitating the study of endothelial cell-leukocyte interaction and the mechanisms underlying immune cell extravasation into the brain. A detailed analysis of the adhesion molecules involved in the recruitment of specific subsets of immune cells into the target organ/tissue could lead to a way for reducing organ-specific inflammation without impairing immunosurveillance.

Such standard and validated models can be used to examine the effects of bacterial and or viral infections, as well as the migration of bacteria- and or virus-infected immune cells, on the permeability of the barrier [250-252]. The developed BBB model can be utilised to study pathogenic mechanisms, hence allowing for the investigation of a broad range of molecular or signalling pathways. Ultimately, studying and developing an optimal and valid BBB model may provide a novel insight into future prevention and a non-antibiotic therapy of pathogenic meningitis [207].

6 ADVANTAGES AND LIMITATIONS OF IN VITRO AND IN VIVO MODELS OF BLOOD-BRAIN BARRIER

The understanding of the BBB is based on the correlation between in vitro and in vivo models and clinical investigations on humans. In vivo animal models can recapitulate the pathological conditions of neuroinfectious diseases in complicated settings. In vivo modelling of BBB physiology captures the multicellular and hemodynamic components of the BBB [253, 254]. Understanding alterations in the BBB and simulating the transport of neurotherapeutics have relied heavily on animal models. Animal models have enabled the in-depth study of the anatomy and biology of the BBB, which is typically only attainable in humans utilising post-mortem tissue. Critical for understanding the role of the BBB at various phases of illness progression, post-mortem tissue does not permit the examination of BBB structure and function in a living individual and at early disease stages [123].

In vitro models of the human BBB are essential for overcoming species variations in BBB modelling and expanding the understanding of the biology of BBB (at the cellular level) in health and illness [255]. In vitro models of the human BBB are commonly used to boost experimental throughput and permit the examination of a wider variety of biological factors in a human-relevant system [256]. Animal and clinical research are frequently preceded and complemented by in vitro BBB models [257, 258].

Preclinical investigations have drawbacks, such as (a) frequently time-consuming and (b) costly, (c) multiple animals are required to generate statistically significant data, (d) ethical problems, and (e) they may lack translational relevance to the human condition [254], This is due to, even though animal models of neuroinfectious diseases express crucial pathological markers, they do not necessarily reflect other biological characteristics of diseases. There are also insufficient animal models for sporadic forms of human disease [259].

The limitations of in vivo models are due to (a) species variations at the genomic (10% difference between human and mouse, 3000 genes) and molecular levels (species-specific expression level of specific proteins) [260]. For example, the response of mice and humans to cytotoxicity or inflammatory stimuli at the barrier [261]. Such differences could impact disease targeting and treatment tactics. A study comparing the expression of genes in BECs of mice and humans discovered a cluster of human-specific genes but none in mice [262]. This may directly impact the pathogenesis of neuroinfectious diseases and hinder the success of animal disease modelling, (b) There are also species-specific variations in protein function, such as the substrate affinity of specific ABC transporters [128], (c) transporter and TJP expression and function differ between the BBBs of rodents and humans. Important TJPs, including ZO-1, occluding, and claudin-5, have greater mRNA expression in mouse BECs than in human BECs [263]. Moreover, a comparison of the protein transporter expression levels in brain microvessels revealed that the expression of specific transporters, such as ABC (P-gp and MRP4) as well as solute carrier transporters (organic anion transporter 3, L-type amino acid transporter, and monocarboxylate transporter 1), was significantly higher in rats than in humans [264]. Positron emission tomography (PET) showed differences in P-gp-dependent drug uptake between rats and humans, with greater P-gp substrate concentrations in human brains than in rat brains [126], (d) O’Brown et al. (2018) describe significant changes in the morphology and gene expression of neocortical cells between the mouse and human. Moreover, the human neocortex is considerably larger and more intricate than the mouse neocortex, which exacerbates medication administration in humans [265]. In addition, the number of astrocytes in the human neocortex is proportionally higher than in the mouse cortex [266], which may influence BBB development and subsequent drug transport. Other NVU cell components have also been shown to exhibit interspecies variations. Rat astrocytes are smaller and have a different process complexity than their human counterparts [67].

In vitro BBB models have “design/manufacturing” limitations, practical limitations, and measurement limitations, such as (a) limited mimicry of BBB and microenvironmental characteristics, e.g., cell-cell/cell-matrix interactions that modify transport exchange mechanisms, (b) inaccurate brain capillary models as a result of inadequate junctional protein and membrane transporter expression, as well as (c) the need to modify culture conditions for each model, ECs might distribute inhomogeneously on the membrane, resulting in poor barriers, (d) efflux functionality and barrier tightness must be improved, (e) current models have larger channel diameters (100-800 m) than in vivo BBB vasculature (capillaries 7-10 m) [165, 267-269].

CONCLUSION

Several high-quality in vitro BBB models have been developed for the in vitro investigation of neuropathological diseases. This review article has been prepared and constructed to discuss the numerous parameters involved in optimising, validating, and maintaining an in vitro BBB, which can serve as a platform and reliable standard system for developing a functional in vitro BBB model in the future. It is well established that the disruption of the BBB accelerates the course of CNS diseases. Therefore, in vitro BBB models are a vital tool to study bacterial, viral, and parasitic invasions of the CNS. We summarised the pathogenic mechanisms implicated in BBB penetration by pathogens that commonly cause neurotrophic disorders in humans. A significant challenge is to apply all of these parameters to simplify our understanding of disease pathogenesis, provide valuable intuitions for improving BBB-neurodisease modelling, modify physiological responses, and accelerate the development of novel clinical approaches and drugs to alleviate the burden of neuroinfectious diseases. In order to achieve clinical and therapeutic outcomes in the near future, it is imperative to continue theorising on neuroinfectious diseases and conducting research using improved BBB models that closely mimic the structural and functional human BBB.

ACKNOWLEDGEMENTS

Declared none.

AUTHOR’S CONTRIBUTIONS

Johnson Stanslas and Hamidon Basri had the idea for the manuscript, the literature search was performed by Ahmad Badawi and Nur Afiqah Mohamad, Ahmad Badawi and Nur Afiqah Mohamad completed the writing-original draft, writing-review and editing were performed by Johnson Stanslas, Brian Kirby, Vasantha Kumari Neela, Rajesh Ramasamy, and Hamidon Basri.

LIST OF ABBREVIATIONS

BBB Blood-brain Barrier

CNS Central Nervous System

EBA Endothelial Barrier Antigen

eNOS Endothelial Nitric Oxide Synthase

FGF Fibroblast Growth Factor

GDNF Glial-derived Neurotrophic Factor

LPS Lipopolysaccharide

MIP2 Macrophage-inflammatory Protein 2

NO Nitric Oxide

SLC Solute-like carrier

TEER Transendothelial Electrical Resistance

TJP Tight Junction Proteins

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

This manuscript was supported by a grant from the University Putra Malaysia (UPM.RMC.800-3/3/1/GP-IPS/2021/ 9701800) and the Malaysian Ministry of Higher Education under the Fundamental Research Grant Scheme (FRGS/1/ 2018/SKK06/UPM/01/2/5540100).

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

Fig. (1) The impact of the selected diseases on BBB parameters. This figure illustrates the effect of Streptococcus pneumoniae, group B streptococcus, Meningitic Escherichia coli Ki, and SARS-CoV-2 on the BBB (attachment, tight junction and basement membrane disruption) as is mentioned later.

Table 1 Cellular components of the blood-brain barrier.

Cells	Characteristics	Functions	Location/Position	Percent of Coverage	Key Markers	Secreting
Factors	
Endothelial cells	• Scarce pinocytotic activity [47].
• Lack of fenestrations (openings) [47].
• Unique expression patterns of trans-membrane transport systems [48].
• Have continuous intercellular TJs.
• Have low expression of leukocyte adhesion molecules [49].
• Have a dynamic interaction with NVU cells. Contributing to their unique characteristics by displaying both endothelial and epithelial features [11, 16, 50].	• Physical barrier (gate function) prevents paracellular diffusion of polar molecules [16].
• Transport barrier includes several active efflux systems with affinity for lipophilic substances [16].
• Metabolic/enzymatic barrier catalyse the oxidation/metabolism of organic substrates, including xenobiotic substances such as drugs and other potentially toxic chemicals [16].	• A monolayer is lining the brain
microvessels [51].	• 100%	• Adherens junction proteins:
a. VE-cadherin
b. PECAM
• Interendothelial tight junction
proteins:
a. ZO-1
b. Claudins
c. Occludins
d. Junctional
adhesion molecules (JAMs)	• PDGFβ	
Pericytes	• Heterogeneous and dynamic cell population, whose expression of surface markers differs corresponding to cell differentiation and tissue distribution [52].
• Contractility [53].
• Multipotential stem cells in the adult brain [53].	• Stabilize nascent vessels and promote vascular maturation [54, 55], contributing to vessel stability, regulating capillary diameter and blood flow and controlling BBB integrity and function [28].
• May coordinate NVU assembly in vivo [56-58].
• The inhibition of transcy-tosis in vivo [56-58].
• Physical connections between pericytes and ECs have been reported transmitting mechanical forces through adhesion plaques [59] and transporting signalling molecules directly through gap junctions [28]).
• Induce the polarization of astrocyte end-feet, and facilitate the attachment of end-feet to CNS vasculature [56].	• Ensheathing the abluminal surfaces of cerebral vessel walls, including capillaries, precapillary arterioles and postcapillary venules [60].
• Wrapping around BMECs on the “brain side”
[61, 62].	• CNS pericytes to ECs ratio 1:3-1:1 [63].
• Contributing 22-32% of the cerebral vasculature [27].	• PDGFR-β
• Α-SMA, NG2 [64].	• Angiopoietin-1 (Ang-1), transforming growth factor-b1
  (TGF-b1) [28], production of basement membrane (BM) components [65].	
Astrocytes	• Star-shaped glial cells.
• Electrically non-excitable cells.
• Heavy expression of the glial fibrillary acidic protein (GFAP) increases with age [66].
• Varicose projection astrocytes [67].
• Exhibiting a high expression of proteins involved in Ca2+ signalling and propagating Ca2+ waves [67, 68].	• Mediating signalling between neurons and BMECs [69].
• Providing nutrition for neurons, regulating extracellular potassium balance, performing neurotransmitter clearance and recycling, controlling immune reactions and regulating the BBB [70].	• Intermediary position.
• Astrocyte processes are terminated in end-feets that are completely ensheathing microvessels and capillaries in the brain [69].	• 99% of the surface of brain microvessels [18].
• Glia-to-neuron ratio is a one-to-one ratio for the whole human adult brain. The human cerebral cortex has a ratio of 1.4 [71, 72].
• Approximately 20~40% of the total number of brain cells [73].	• Gap junction: Connexin30 and connexin43 [74]. ZO-1 [74]. ZONAB (ZO-1-associated nucleic acid-binding protein) [74]. GFAP and vimentin
[75, 76].	• IL-6 [77].
• Glial cell line-derived neurotrophic factor [32].
• Fibroblast growth factor 2 [78].
• Transforming growth factor β1 [79].	
Neurons	• Electrically excitable cells.
• Mature neurons do not divide.
• Neurons release neurotransmitters into synapses, or the connections between cells, to communicate with other neurons.	• The role of neurons in regulating BBB function remains poorly understood.	• Located on average, 10-20 μm from the nearest capillary [35].	• NA	• NeuN [80].
• Beta-III tubulin [81].
• Neurofilament high [81].	• Sonic Hedgehog (SHH) [34].
• Platelet-activating factor (PAF) [82].	
Microglia	• Regional heterogeneity of microglial gene signatures [83].
• Complex and dynamic microglia phenotypes.
• Dichotomous paradigm; represents a large spectrum of activation states and is often related to inflammatory reactions and morphological changes [84].
• Exhibiting region-specific responses [85].
• The only myeloid cells reside in the healthy CNS parenchyma [86].
• Microglia’s unique ontogeny, resident microglial cells in the healthy adult brain persist during adulthood via constant self-renewal without turnover from circulating blood progenitors [87, 88].
• The fastest-moving structures in the healthy adult brain, monitoring the entire brain parenchyma in less than four hours [78, 79].	• Vessel-associated microglia initially maintain BBB integrity via expression of the tight-junction protein claudin-5 and make physical contact with endothelial cells. During inflammation, microglia phagocytose astrocytic end-feet and impair BBB function [45].
• Microglia adjacent to the BBB are in constant bi-directional communication with endothelial cells, facilitating microglial cells to do their surveying functions on the BBB integrity and the influx of blood-derived molecules into the brain [89, 90].	• Locating at the proximal region surrounding the cerebrovasculature, allowing a close endothelium-microglia interaction [91].	• 12-16% of the total brain population [92].	• All microglia:
• Iba-1 [93].
• Activated microglia: major histocompatibility complex (MHC) class I and II molecules [94, 95].	• Activated microglia: TNFα, IL-1β [96, 97] nerve growth factor (NGF), neurotrophin (NT)-4/5, transforming growth factor (TGF)-β1, glial-derived neurotrophic factor (GDNF), fibroblast growth factor (FGF), and
IL-3 [98].	
Abbreviations: NA, not available; VE-, vascular endothelial; PECAM, platelet endothelial cell adhesion molecule; ZO-1, zonula occludens-1; PDGFβ, Platelet-derived growth factor subunit B; ECs, endothelial cells; BMECs, brain microvascular endothelial cells; PDGFR-β, Platelet-derived growth factor receptor-β; Α-SMA, alpha-smoot muscle actin; NG2, neuron-glial antigen 2; Iba-1, ionized calcium-binding adaptor protein-1; IL: interleukin, TNFα, tumour necrosis factor-alpha.

Table 2 The advantages and disadvantages of the current models of BBB.

BBB Models	Advantages	Disadvantages	References	
Endothelial
monoculture	• Microscopic observation
• Molecular cell analysis	• Absence of cell-cell interactions in the BBB
• Endothelial phenotypes are limited
• Insufficient BBB characteristics
• Absent blood or media flow
• Absent shear stress
• Formation of monolayer	[122-127]	
Transwell system	• BBB cells interaction
• Enhancement of BBB's physical properties
• Endothelial cell phenotypes enhancement
• Formation of a stricter and more selective vascular bed
• Suitable for leukocyte transmigration	• Enhancement of BBB’s physical properties
• Absent of cell-cell interaction in the BBB
• Absent blood or media flow
• Absent shear stress	[122-127]	
3D ECM-based BBB	• Utilizing self-polymerizing ECM protein scaffolds
• BBB cellular components are capable of developing close connections	• It is not widely used in BBB research
• The difficulty of constructing a matrix architecture resembling in vivo
• These systems are limited to fundamental research at present	[124]	
Organoid BBB	• Each cell type is in close interaction with every other cell type within the organoid
• Increased expression of tight junctions, adherens junctions, and efflux pump
• Ease of culture
• Simple
• Fewer reagents are required
• Small size
• Cost-effectiveness
• Reproducibility	• Inter-samples variability
• High processing time
• The absence of essential types of cells, including glia, microglia, oligodendrocytes thus limiting its utilities for specific disease models	[87, 88, 98]	
DIV-BBB	• Distribution of BBB cells topographically
• Blood or media flow
• Capillary-like shear stress
• Enhancement of BBB’s physical properties
• Enhancement BBB phenotypes	• Large vascular bed
• Undistinguishable cell-cell interaction
• Restricted leukocyte migration	[122-127]	
Microfluid model	• Microvasculature-like microchannels
• Enhancement of BBB’s physical properties
• Blood or media flow
• Real-time evaluation of BBB properties
• Similar to physiological shear stress	• Limitation in cell-cell contact production
• Fixed ECM
• Limited real-time evaluation of BBB properties	[122-127]	
BBB-on-a-chip	• Microvasculature like microchannels
• Enhancement of BBB’s physical properties
• Blood or media flow
• Similar to Physiological shear stress
• Real-time evaluation of BBB properties	• Reproducibility of cell phenotype and capillary size is restricted.	[122-127]	
Abbreviations: 3D, thee-dimensional; ECM, extrasellar matrix; DIV-BBB, dynamic in vitro BBB.

Table 3 Structural, functional, and molecular characteristics of the ideal in vitro human BBB model.

Structural Characteristics	
• Expression of tight endothelial junctions.
• Expression of drug-metabolizing enzymes (e.g., P450s).
• Exposure to laminal shear stress (apical membrane), glia (basal membrane), and other permissive factors induces growth inhibition and endothelial cell differentiation.	
Functional Characteristics	
• Insignificant paracellular diffusion.
• Selective and asymmetric permeability to physiologically essential ions.
• Functional expression of efflux pumps and selective transport systems (e.g., P-gp, amino acid, hexose).
• Sensitivity to permeation modulators (e.g., hyperosmolar mannitol) and other endogenous and exogenous stimuli can alter BBB function and integrity.
• Capability to imitate the effect of diverse physiological and pathological stimuli (e.g., hypertension, inflammation) that affect the in vivo BBB.	
Molecular Characteristics	
• Molecular expression of interactions between BBB cells.
• Molecular expression of the junctional complex (adherens and tight).
• Molecular expression of ATP-binding Cassette (ABC) and SLC Transporters of the BBB.	
Abbreviations: P450, Cytochromes P450; SLC, solute-like carrier. Modified from [132].

Table 4 Optimization parameters of in vitro blood-brain barrier model.

Parameters	Purpose	Property	Assay/Techniques	References	
Cell confluence,
non-overlapping,
uniform monolayer	• Effect on TEER.
• An even and flattened morphology predominantly organised in a single layer.	Integrity	Microscopic observation, immunostaining & TEER measurement	[155, 160-161]	
Cell seeding density	• Forming a functional BBB.
• Cell growth and TJ development between adjacent cells.
• Low or high cell seeding density caused decreased maximal TEER values.	Tightness & integrity	TEER measurement	[160, 162]	
Cell viability	• Maintain the viability of primary human cells.
• Maintain the viability of BBB.
• Assess the impact of different factors on the cellular viability of BBB.	Tightness & integrity	Trypan blue exclusion method,
MTT cellular viability assay	[122, 162, 163]	
Nature of cell type	• Effect on TEER.
• Confirming that the cells used are of human origin.	Mimic human BBB	DNA fingerprinting as analysed by both ICC and FC	[147, 162, 164]	
Co-culturing with cellular components of the NVU	• Mimic in vivo BBB.
• More stable.
• Physiologically relevant.	Barrier function and integrity	In vitro BBB modelling	[162, 165]	
Cell organization	• Closer representation of in vivo BBB.
• Would be in direct contact, allowing them to exchange vital growth factors required for cellular growth and development.	Barrier function and integrity	TEER measurement	[165]	
Timeline establishment of model	• Effect on TEER.
• BBB physiology.	Barrier function and integrity	In vitro BBB modelling	[165]	
Passage number of cells	• Effect on BBB phenotypes.
• Dedifferentiation process.	Barrier function and integrity	Microscopic observation, immunostaining & TEER measurement	[166, 166-168]	
Cultivation period	• Effect on TEER
• Extended to allow the proper formation of interendothelial tight and adherens junctions.	Tightness	Immunostaining
TEER measurement	[155]	
Culture Conditions	
Co-culture Conditions	
Co-culture media	• Expression of endothelial markers.
• Tight junction proteins.
• Endocytosis machinery and P-gp efflux transporter.
• High TEER.
• Increased cell density.	Barrier function, tightness, integrity and improved the quality	TEER & permeability measurements, immunostaining	[169]	
Cell ratio	• Increased TEER.
• Improved tight junction continuity.	Performance of co-culture and multicultural models	TEER & permeability measurements, immunostaining	[131]	
Cell-media volume ratios	Avoid dilution of co-culture signals and metabolites.	Performance of co-culture and multicultural models	TEER & permeability measurements	[170]	
Culture surface/volume ratios	Obtaining good cell growth and differentiation.	Performance of cell culture	Cell proliferation assay and cell cytotoxicity	[170]	
Growth Medium Compositions	
Serum (human)	• Mimic in vivo.
• No increase in TEER could be observed.
• The permeability of sucrose through hCMEC/D3 monolayers could significantly be reduced by HS supplementation.	Integrity	Permeability measurement	[160, 171]	
Concentration	Low TEER values might also arise from a high concentration of serum and growth factors in the growth medium.	Integrity	TEER measurement	[155, 160]	
Supplement	Medium supplemented with L-glutamine, and the reduction of the serum concentration decelerates cell growth and promotes differentiation.	Physical barrier	TEER & permeability measurements	[155]	
Cell culture support materials	Allow cell differentiation, interaction and response.	Integrity	Microscopic observation, immunostaining, attachment and spreading assay & TEER measurement	[132]	
Extracellular Matrix (ECM)	
Cell-derived matrices	Maintain some of the original gaps that accommodate the cells.	Tightness	Permeability measurement	[172, 173]	
Transwell Apparatus	
1. Membrane materials	Impact on the adherence of cells and barrier tightness.	Barrier tightness	TEER & permeability measurements	[174, 175]	
2. Pore size	Impact on the adherence and migration of cells and barrier tightness.	Barrier tightness	TEER & permeability measurements	[165, 174, 175]	
3. Coating materials	Impact on cell growth and TJ development between adjacent cells.	Tightness & integrity	TEER & permeability measurements	[160]	
4. Coating procedures	Impact on the adherence of cells and barrier tightness	Barrier tightness	TEER & permeability measurements	[160]	
5. Well format	The selection of the well format might affect TEER values.	Barrier strength	TEER measurement	[160, 165]	
6. Surface area	More surface area, more growth area.	Barrier strength	TEER measurement	[155]	
Assay/Technique	
TEER	Real-time monitoring	Integrity	EVOM: Manual cell monitoring
CellZscope system: automated cell monitoring
ECIS: automated cell monitoring
xCelligence: automated cell monitoring	[162]	
TEER electrodes:
Size, gap, orientation	Minimizing background resistance and error.	Integrity	TEER measurement	[170]	
Mechanical Factors	
Shear stress	• Increase cell longevity.
• Influence cell phenotype.
• Regulate BBB transport.
• Preventing de-differentiation.	Barrier function	Endothelial morphology, proliferation, apoptosis, and motility	[176-179]	
Flow rates	Polarized BBB endothelium phenotype.	Barrier function	Endothelial morphology, proliferation, apoptosis, and motility	[132]	
Abbreviations: TEER, transendothelial electrical resistance; TJ, tight junction; P-gp, P-glycoprotein; ICC, immunocytochemistry; FC, flow cytometry.

Table 5 Validation parameters of in vitro blood-brain barrier model and advantages and limitations of the methods.

Parameters	Principle	Purpose	Advantages	Limitations	References	
TEER measurement	Chopstick electrodes or built-in electrodes	Tightness of BBB	• Quantitative technique
• To quantify the electrical resistance
• Non-invasive
• Simple, rapid and reliable
• TEER values are a strong indicator of the integrity of the BBB.
• TEER measurements can be performed in real-time and based on measuring ohmic resistance or impedance.
• The method can be applied to monitor live cells	• When reporting TEER values, laboratories should identify and report variables and the exact conditions under which TEER measurements were performed (the accuracy of the measurement techniques based on selection and usage of electrodes, temperature during measurement, medium formulation, cell culture period and passage number of cells used).	[156]	
Permeability
measurement	Fluorescently
labelled small molecules or small radiolabelled molecules	Tightness of BBB	• Quantitative concentration measurement
• To quantify the paracellular permeability
• TJ barrier formation
• To study the transport of tracer substances and drugs
• Apparent Permeability of test compounds in either the apical or basal direction
• Change in Apparent Permeability of BBB due to effect of a drug compound or pathogen	• Is typically performed at a single type of point of an experiment
• Need for repeated sampling of luminal and brain side fluids.
• Invasiveness.	[161, 184] [185]	
Cell viability	CFDA staining	Monolayer
integrity	• Quantitative analysis of viable cells
• Advantages depend on which assay is used.	• Limitation depends on which assay is used.	[186]	
Cellular
morphology	Microscopic analysis	Monolayer integrity and BBB function	• Non-staining observation method
• Live cells
• Non-invasive
• Simple and rapid
• Observe morphological characteristics, typical normal and abnormal morphology
• Provide general information on the size, shape, and growth of cells
• Morphological cell analysis; quantitative characterization of cell morphology.	• Unable to provide comprehensive information about the dynamic morphology.	[163]	
CFDA/CMO staining	CFDA and CMO staining	Monolayer
integrity	• Detect continuous membrane contacts in confluent cultures and the intercellular gaps.
• Measures enzymatic activity and cell-membrane integrity.
• Simple
Long-term retention	• Minimal cytotoxicity.	[187]	
Cell confluence	Microscopic observation, immunostaining & TEER measurement	Integrity of BBB	• One of the essential characteristics of an in vitro model for endothelial permeability.
• Microfilament is formed as endothelial cells grow to confluence. The DPB only appears once the cultures have reached confluence.
• Ability of ECs to form and maintain the EC monolayer.
• Affect cell morphology.
• AJ organisation varies at various stages of cell confluence.
• Control permeability.	-	[160, 161] [188, 189]	
Continuity of membrane contacts	Assessing using a plasma membrane stain, CMO	Monolayer
integrity	-	-	[186]	
BBB cells markers expression	Immunostaining & Western blot	Characterization of BBB cells and BBB function	Immunostaining
• Observe the subcellular localization and expression of AJ, TJ, ECM, and cell surface markers.
• Detect multiple targets.
• Qualitative and quantitative analysis of expression of cell proteins.
• It also depends on the types of immunostaining used (IF (direct or indirect), ICC (direct or indirect).
Western blot
• Qualitative and quantitative expression of AJ, TJ, and ECM proteins.
• It also depends on the types of detection the system (colorimetric, chemiluminescent, or fluorescent) and direct or indirect method used
Electron microscopy
• Observe minute structural alterations, surface structural alterations, and internal structural alterations.
• Observe TJ formation.
• Check for the formation of monolayer or multilayer.
• It also depends on the types of electron microscopy used (TEM, SEM, and immunoelectron microscopy).	Immunostaining
• Fixing cells (nor live cells).
• Non-specific binding.
• Require antibody specificity and validation.
• It also depends on the types of immunostaining used.
Western blot
• Require specialized detection and imaging systems.
• Contaminations cause high background signals.
• Require antibody specificity and validation.
• It also depends on the types of detection and direct or indirect method used.
Electron microscopy
• Expensive
• Inability to analyse live cells.
• It also depends on the types of electron microscopy used.	[184]	
Tight junction proteins expression	Immunostaining & Western blot (mRNA and protein expression - localization), electron microscopy	Tightness of BBB	[184, 124]	
Efflux
transporters	mRNA and protein expression	Transendothelial transport	Gene expression
• Not limited to known characteristics; permits evaluation of a large “discovery set”.
• Objective and quantitative interpretation.
• Effects of preanalytical variability can be assessed with RNA quality.
• It also depends on the types of assays used.	Gene expression
• Potential contamination.
• Technically challenging to apply to fixed tissues.
• Preanalytical variability (RNA quality).
• It also depends on the types of assays used.	[190, 191]	
SLC transporter	mRNA and protein expression	Transendothelial transport	[192, 193]	
Receptor
systems	mRNA and protein expression	Receptor-mediated transport	[194]	
Responsiveness to regulation induced by NVU cells	Astrocytes induction:
Regulation of TEER, P-gp expression and cell morphology
Pericytes induction:
Regulation of TEER,
proteins involved in
vesicular transport	Cell regulation and NVU signalling	-	-	[34, 56, 195]	
Immune cell
transmigration	The transmigration of calcein-labelled PBMCs	The barrier for immune cells	-	-	[155]	
Abbreviations: CFDA, Carboxyfluorescein diacetate; CMO, CellMask Orange; PBMCs, peripheral blood mononuclear cells; DPB, dense peripheral band; IF, immunofluorescence; ICC, immunocytochemistry; TEM, transmission electron microscopy; SEM, scanning electron microscopy. DPB, dense peripheral band; IF, immunofluorescence; ICC, immunocytochemistry; TEM, transmission electron microscopy; SEM, scanning electron microscopy.

Table 6 Applications of in vitro blood-brain barrier model in neuroinfectious diseases studies.

Infectious Agents/ Inflammatory Markers	Route	Mechanism	Impact on the BBB	Model	Disease	Key
Effector(s) (Correlation)	References	
Meningitic
E. coli	NA	• Functional involvement of PDGF-BB and ICAM-1 in meningitic E. coli invasion of the BBB.
• SphK2-S1P-S1P2-EGFR-c-Src signalling cascade.
• PCN033 induction of VEGFA and Snail-1 activation of TLR2-MAPK-ERK1/2 signalling.	• Induce production and secretion of PDGF-BB enhance permeability by: -Decrease TEER. -Downregulating TJP expression (ZO-1, occludin, claudin-5). -Increase ICAM-1 expression.
• PCN033 increased the BBB permeability via: -Downregulating and disrupting the TJP (ZO-1, β-catenin, occludin, claudin-5). -Upregulation of VEGFA. -Induction of snail-1 negatively regulates the TJ protein expression.	In vitro hBMEC model	Bacterial meningitis	The bacteria and proinflammatory cytokines/ chemokines	[105, 207, 208]	
S. pneumoniae	NA	• LR-pneumococcal CbpA interaction	• No significant disruption of endothelial integrity.	Mouse and human BMECs in vitro model	Pneumococcal meningitis	NA	[209, 210]	
Group B
Streptococcus	NA	• SfbA-fibronectin-integrin interaction	• Disruption of the tight junction proteins.	hBMEC in vitro, iPSC-derived BMEC model	Streptococcal meningitis	NA	[211, 212]	
SARS-CoV-2	Endocytosis?
Trojan horse?
Intracellular transmigration	• Spike protein-ACE2 interactions	• Alter the BBB integrity
  o Reduce TEER
  o Increase passive paracellular permeability
  o Decreased ZO-1 localisation to cell-cell junctions.
  o Structural reconfiguration.
  o Decrease TJ proteins expression: ZO-2, Claudin-5, JAM-2.
• Increased ECM enzymes (MMP3.
• Increased cell adhesion molecules (VCAM-1 and ICAM-1).
• Increased endothelial pro-inflammatory response (CCL5, CXCL10).	In vitro hBMEC model, 2D & 3D human BBB model	COVID-19-associated neurological disease	The virus and structural reconfiguration of TJ proteins, proinflammatory cytokines/
chemokines	[224, 226]	
HIV-1	NA	NA	• Reduced expression of Cx43,
a-SMA), α1-integrin, and PDGF-Rβ).
• Increase in inflammatory factor secretion.
• Adhesion molecules upregulation.
• Development of a migratory phenotype.
• Disruption of BBB.
• Downregulation of fibronectin and nidogen in pericytes.
• Reduction in TIMP3.	hBMVEC-brain pericytes co-culture model with monocyte adhesion/
migration	HIV-1-associated neurocognitive disorder	NA	[235]	
Semliki forest virus (SFV)	Transcellular	Lysine facilitated viruses with the most significant reliance on binding to GAGs more efficiently crossed an in vitro BBB.	Significant reduction in TEER	In vitro human BBB	Virus encephalitis	The ability to replicate in the brain	[214]	
Japanese encephalitis virus (JEV)	Passive diffusion	JEV is able to infect endothelial cells, release pro-inflammatory markers from these cells, increased permeability of BBB, infect astrocytes, release pro-inflammatory markers.	Drop in TEER	In vitro human BBB	Encephalitis	Inflammatory cytokines/ chemokines from HBECs and astrocytes	[13]	
Dengue virus (DENV)	Transcellular, paracellular,
‘Trojan horse’	NA	• Decrease TEER.
• Increase permeability.
• Subcellular localization of ZO-1 and claudin-1.
• Transmigration of monocytes/macrophages.	In vitro MBECs model in vitro MBECs-astrocytes model	DENV infection	The virus and inflammatory cytokines/ chemokines	[239]	
Zika virus (ZIKV)	Transcellular	NA	Without compromising TEER and paracellular permeability or the viability of the i-BEC monolayer.	The human iPSC-derived i-BEC, i-NPs and i-Ns BBB model	ZIKA infection	The virus and AXL-mediated ZIKV entry	[186]	
HCV	receptor-dependent entry pathway	HCVpp and VSV-Gpp receptors hCMEC/D3 and HBMEC interaction	Disrupt endothelial cell integrity
  o Increased paracellular permeability.	hCMEC/D3 and HBMEC in vitro BBB model	HCV
infection-associated neuropathology	Direct infection	[245]	
African
trypanosome	Transmigration	NA	NA	ECV304-C6 BBB model	African trypanosome infection	Increase of the trypanosomal inoculum	[246]	
P. berghei
P. falciparum	Cross-presentation of PbA, cytoadherence	hICAM-1 of hCMEC/D3 cells and a trypsin-sensitive antigen of
P. falciparum RAOL cytoadherence	• Disorganization of ZO1
• Increased endothelial cell permeability.	In vitro MBECs PbA cross-presentation model, co-culture of
P. falciparum RAOL-PRBCs and hCMEC/D3 cells model	CM	NA	[247, 24]	
Taenia solium
T. gondii	Leukocyte transendothelial migration pathway,
‘Trojan horse’	NA	• Overexpressed of VEGF-A in astrocytes.
• BBB disruption
• -Decreased immunoreactivity to EBA marker.
• -Increased permeability for IgG.
• Upregulation of ICAM-1.
• Increased IL-6 and MCP-1.	In vitro HUVEC model, rat brain endothelial and glial cells in vitro BBB model.	Neurocysticercosis	Parasite itself	[108, 249]	
Abbreviations: NA, not available; PDGF-BB, platelet-derived growth factor-BB; ICAM-1 intracellular adhesion molecule-1; VEGFA, vascular endothelial growth factor A; ZO-1, zonula occludens-1; TJ, tight junction; hBMEC, human brain microvascular endothelial cell; GAGs, glycosaminoglycans; HBECs, human brain endothelial cells; i-BEC, induced-brain endothelial cells; iPSC, induced-pluripotent stem cells; i-NPs, induced-neural progenitor cells; i-Ns, induced-mature neurons; αSMA, alpha smooth muscle actin; PDGF-Rβ, platelet-derived growth factor-B receptor; VCAM, vascular cell adhesion molecule; HUVEC, human umbilical vein endothelial cell.
==== Refs
REFERENCES

1 Abbott N.J. Future perspectives. Blood-brain barrier in drug discovery: optimizing brain exposure of cns drugs and minimizing brain side effects for peripheral drugs. Di L. Kerns E.H. Wiley 2015 1 586 10.1002/9781118788523.ch26
2 Burkhart A. Thomsen L.B. Thomsen M.S. Lichota J. Fazakas C. Krizbai I. Moos T. Transfection of brain capillary endothelial cells in primary culture with defined blood-brain barrier properties. Fluids Barriers CNS 2015 12 1 19 10.1186/s12987-015-0015-9 26246240
3 Kim K.S. Pathogenesis of bacterial meningitis: From bacteraemia to neuronal injury. Nat. Rev. Neurosci. 2003 4 5 376 385 10.1038/nrn1103 12728265
4 Kim K.S. Mechanisms of microbial traversal of the blood-brain barrier. Nat. Rev. Microbiol. 2008 6 8 625 634 10.1038/nrmicro1952 18604221
5 Candelario-Jalil E. Yang Y. Rosenberg G.A. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009 158 3 983 994 10.1016/j.neuroscience.2008.06.025 18621108
6 Verma S. Kumar M. Gurjav U. Lum S. Nerurkar V.R. Reversal of West Nile virus-induced blood-brain barrier disruption and tight junction proteins degradation by matrix metalloproteinases inhibitor. Virology 2010 397 1 130 138 10.1016/j.virol.2009.10.036 19922973
7 Roberts T.K. Buckner C.M. Berman J.W. Leukocyte transmigration across the blood-brain barrier: Perspectives on neuroAIDS. Front. Biosci. 2010 15 1 478 536 10.2741/3631 20036831
8 Greenwood J. Heasman S.J. Alvarez J.I. Prat A. Lyck R. Engelhardt B. Review: Leucocyte-endothelial cell crosstalk at the blood-brain barrier: A prerequisite for successful immune cell entry to the brain. Neuropathol. Appl. Neurobiol. 2011 37 1 24 39 10.1111/j.1365-2990.2010.01140.x 20946472
9 Winger R.C. Koblinski J.E. Kanda T. Ransohoff R.M. Muller W.A. Rapid remodeling of tight junctions during paracellular diapedesis in a human model of the blood-brain barrier. J. Immunol. 2014 193 5 2427 2437 10.4049/jimmunol.1400700 25063869
10 Varatharajan L. Thomas S.A. The transport of anti-HIV drugs across blood-CNS interfaces: Summary of current knowledge and recommendations for further research. Antiviral Res. 2009 82 2 A99 A109 10.1016/j.antiviral.2008.12.013 19176219
11 Deli M.A. Ábrahám C.S. Kataoka Y. Niwa M. Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell. Mol. Neurobiol. 2005 25 1 59 127 10.1007/s10571-004-1377-8 15962509
12 Patabendige A. The value of in vitro models of the blood-brain barrier and their uses. Altern. Lab. Anim. 2012 40 6 335 338 10.1177/026119291204000606 23398338
13 Patabendige A. Michael B.D. Craig A.G. Solomon T. Brain microvascular endothelial-astrocyte cell responses following Japanese encephalitis virus infection in an in vitro human blood-brain barrier model. Mol. Cell. Neurosci. 2018 89 60 70 10.1016/j.mcn.2018.04.002 29635016
14 Abbott N.J. Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 2002 200 6 629 638 10.1046/j.1469-7580.2002.00064.x 12162730
15 Sims D.E. Diversity within pericytes. Clin. Exp. Pharmacol. Physiol. 2000 27 10 842 846 10.1046/j.1440-1681.2000.03343.x 11022980
16 Abbott N.J. Rönnbäck L. Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006 7 1 41 53 10.1038/nrn1824 16371949
17 Dohgu S. Takata F. Yamauchi A. Nakagawa S. Egawa T. Naito M. Tsuruo T. Sawada Y. Niwa M. Kataoka Y. Brain pericytes contribute to the induction and up-regulation of blood-brain barrier functions through transforming growth factor-β production. Brain Res. 2005 1038 2 208 215 10.1016/j.brainres.2005.01.027 15757636
18 Hawkins B.T. Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 2005 57 2 173 185 10.1124/pr.57.2.4 15914466
19 Chaudhuri J.D. Blood brain barrier and infection. Med. Sci. Monit. 2000 6 6 1213 1222 11208482
20 de Boer A.G. Gaillard P.J. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol. 2007 47 1 323 355 10.1146/annurev.pharmtox.47.120505.105237 16961459
21 Harhaj N.S. Antonetti D.A. Regulation of tight junctions and loss of barrier function in pathophysiology. Int. J. Biochem. Cell Biol. 2004 36 7 1206 1237 10.1016/j.biocel.2003.08.007 15109567
22 Kniesel U. Wolburg H. Tight junctions of the blood-brain barrier. Cell. Mol. Neurobiol. 2000 20 1 57 76 10.1023/A:1006995910836 10690502
23 Schulze C. Firth J.A. Immunohistochemical localization of adherens junction components in blood-brain barrier microvessels of the rat. J. Cell Sci. 1993 104 3 773 782 10.1242/jcs.104.3.773 8314872
24 Vorbrodt A.W. Dobrogowska D.H. Molecular anatomy of interendothelial junctions in human blood-brain barrier microvessels. Folia Histochem. Cytobiol. 2004 42 2 67 75 15253128
25 Wolburg H. Lippoldt A. Tight junctions of the blood-brain barrier. Vascul. Pharmacol. 2002 38 6 323 337 10.1016/S1537-1891(02)00200-8 12529927
26 Bagley R.G. Weber W. Rouleau C. Teicher B.A. Pericytes and endothelial precursor cells: Cellular interactions and contributions to malignancy. Cancer Res. 2005 65 21 9741 9750 10.1158/0008-5472.CAN-04-4337 16266995
27 Dore-Duffy P. Pericytes: Pluripotent cells of the blood brain barrier. Curr. Pharm. Des. 2008 14 16 1581 1593 10.2174/138161208784705469 18673199
28 Winkler E.A. Bell R.D. Zlokovic B.V. Central nervous system pericytes in health and disease. Nat. Neurosci. 2011 14 11 1398 1405 10.1038/nn.2946 22030551
29 Hori S. Ohtsuki S. Hosoya K. Nakashima E. Terasaki T. A pericyte‐derived angiopoietin‐1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie‐2 activation in vitro. J. Neurochem. 2004 89 2 503 513 10.1111/j.1471-4159.2004.02343.x 15056293
30 Levéen P. Pekny M. Gebre-Medhin S. Swolin B. Larsson E. Betsholtz C. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev. 1994 8 16 1875 1887 10.1101/gad.8.16.1875 7958863
31 Lindahl P. Johansson B.R. Levéen P. Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science (80-) 1997 277 5323 242 245
32 Igarashi Y. Utsumi H. Chiba H. Yamada-Sasamori Y. Tobioka H. Kamimura Y. Furuuchi K. Kokai Y. Nakagawa T. Mori M. Sawada N. Glial cell line-derived neurotrophic factor induces barrier function of endothelial cells forming the blood-brain barrier. Biochem. Biophys. Res. Commun. 1999 261 1 108 112 10.1006/bbrc.1999.0992 10405331
33 Ifergan I. Kebir H. Terouz S. Alvarez J.I. Lécuyer M.A. Gendron S. Bourbonnière L. Dunay I.R. Bouthillier A. Moumdjian R. Fontana A. Haqqani A. Klopstein A. Prinz M. López-Vales R. Birchler T. Prat A. Role of ninjurin‐1 in the migration of myeloid cells to central nervous system inflammatory lesions. Ann. Neurol. 2011 70 5 751 763 10.1002/ana.22519 22162058
34 Alvarez JI Dodelet-Devillers A Kebir H Ifergan I Fabre PJ Terouz S The hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science (80-) 2011 334 6063 1727 1731 10.1126/science.1206936
35 Schlageter K.E. Molnar P. Lapin G.D. Groothuis D.R. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc. Res. 1999 58 3 312 328 10.1006/mvre.1999.2188 10527772
36 Hellström M. Gerhardt H. Kalén M. Li X. Eriksson U. Wolburg H. Betsholtz C. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell Biol. 2001 153 3 543 554 10.1083/jcb.153.3.543 11331305
37 Kacem K. Lacombe P. Seylaz J. Bonvento G. Structural organization of the perivascular astrocyte endfeet and their relationship with the endothelial glucose transporter: A confocal microscopy study. Glia 1998 23 1 1 10 10.1002/(SICI)1098-1136(199805)23:1<1:AID-GLIA1>3.0.CO;2-B 9562180
38 Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008 57 2 178 201 10.1016/j.neuron.2008.01.003 18215617
39 Man S. Ubogu E.E. Ransohoff R.M. Inflammatory cell migration into the central nervous system: A few new twists on an old tale. Brain Pathol. 2007 17 2 243 250 10.1111/j.1750-3639.2007.00067.x 17388955
40 Tontsch U. Bauer H.C. Glial cells and neurons induce blood-brain barrier related enzymes in cultured cerebral endothelial cells. Brain Res. 1991 539 2 247 253 10.1016/0006-8993(91)91628-E 1675906
41 Savettieri G. Liegro I.D. Catania C. Licata L. Pitarresi G.L. DʼAgostino, S.; Schiera, G.; De Caro, V.; Giandalia, G.; Giannola, L.I.; Cestelli, A. Neurons and ECM regulate occludin localization in brain endothelial cells. Neuroreport 2000 11 5 1081 1084 10.1097/00001756-200004070-00035 10790886
42 Pulido R.S. Munji R.N. Chan T.C. Quirk C.R. Weiner G.A. Weger B.D. Rossi M.J. Elmsaouri S. Malfavon M. Deng A. Profaci C.P. Blanchette M. Qian T. Foreman K.L. Shusta E.V. Gorman M.R. Gachon F. Leutgeb S. Daneman R. Neuronal activity regulates blood-brain barrier efflux transport through endothelial circadian genes. Neuron 2020 108 5 937 952.e7 10.1016/j.neuron.2020.09.002 32979312
43 Rhea E.M. Banks W.A. Role of the blood-brain barrier in central nervous system insulin resistance. Front. Neurosci. 2019 13 521 10.3389/fnins.2019.00521 31213970
44 Fabriek B.O. Van Haastert E.S. Galea I. Polfliet M.M.J. Döpp E.D. Van Den Heuvel M.M. Van Den Berg T.K. De Groot C.J.A. Van Der Valk P. Dijkstra C.D. CD163‐positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia 2005 51 4 297 305 10.1002/glia.20208 15846794
45 Haruwaka K. Ikegami A. Tachibana Y. Ohno N. Konishi H. Hashimoto A. Matsumoto M. Kato D. Ono R. Kiyama H. Moorhouse A.J. Nabekura J. Wake H. Dual microglia effects on blood brain barrier permeability induced by systemic inflammation. Nat. Commun. 2019 10 1 5816 10.1038/s41467-019-13812-z 31862977
46 Joost E. Jordão M.J.C. Mages B. Prinz M. Bechmann I. Krueger M. Microglia contribute to the glia limitans around arteries, capillaries and veins under physiological conditions, in a model of neuroinflammation and in human brain tissue. Brain Struct. Funct. 2019 224 3 1301 1314 10.1007/s00429-019-01834-8 30706162
47 Abbott N.J. Patabendige A.A.K. Dolman D.E.M. Yusof S.R. Begley D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis. 2010 37 1 13 25 10.1016/j.nbd.2009.07.030 19664713
48 Stewart P.A. Wiley M.J. Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: A study using quail-chick transplantation chimeras. Dev. Biol. 1981 84 1 183 192 10.1016/0012-1606(81)90382-1 7250491
49 Kadl A. Leitinger N. The role of endothelial cells in the resolution of acute inflammation. Antioxid. Redox Signal. 2005 7 11-12 1744 1754 10.1089/ars.2005.7.1744 16356135
50 Cecchelli R. Berezowski V. Lundquist S. Culot M. Renftel M. Dehouck M.P. Fenart L. Modelling of the blood-brain barrier in drug discovery and development. Nat. Rev. Drug Discov. 2007 6 8 650 661 10.1038/nrd2368 17667956
51 Emmi A. Wenzel H.J. Schwartzkroin P.A. Taglialatela M. Castaldo P. Bianchi L. Nerbonne J. Robertson G.A. Janigro D. Do glia have heart? Expression and functional role for ether-a-go-go currents in hippocampal astrocytes. J. Neurosci. 2000 20 10 3915 3925 10.1523/JNEUROSCI.20-10-03915.2000 10804231
52 Sá-Pereira I. Brites D. Brito M.A. Neurovascular unit: A focus on pericytes. Mol. Neurobiol. 2012 45 2 327 347 10.1007/s12035-012-8244-2 22371274
53 Dore-duffy P. Cleary K. Morphology and properties of pericytes. The Blood-Brain and Other Neural Barriers Methods in Molecular Biology (Methods and Protocols). Nag S. Humana Press 2011 10.1007/978-1-60761-938-3_2
54 Armulik A. Genové G. Betsholtz C. Pericytes: Developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 2011 21 2 193 215 10.1016/j.devcel.2011.07.001 21839917
55 Sweeney M.D. Ayyadurai S. Zlokovic B.V. Pericytes of the neurovascular unit: Key functions and signaling pathways. Nat. Neurosci. 2016 19 6 771 783 10.1038/nn.4288 27227366
56 Armulik A. Genové G. Mäe M. Nisancioglu M.H. Wallgard E. Niaudet C. He L. Norlin J. Lindblom P. Strittmatter K. Johansson B.R. Betsholtz C. Pericytes regulate the blood-brain barrier. Nature 2010 468 7323 557 561 10.1038/nature09522 20944627
57 Ben-Zvi A. Lacoste B. Kur E. Andreone B.J. Mayshar Y. Yan H. Gu C. Mfsd2a is critical for the formation and function of the blood-brain barrier. Nature 2014 509 7501 507 511 10.1038/nature13324 24828040
58 Daneman R. Zhou L. Kebede A.A. Barres B.A. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 2010 468 7323 562 566 10.1038/nature09513 20944625
59 Gerhardt H. Wolburg H. Redies C. N‐cadherin mediates pericytic‐endothelial interaction during brain angiogenesis in the chicken. Dev. Dyn. 2000 218 3 472 479 10.1002/1097-0177(200007)218:3<472:AID-DVDY1008>3.0.CO;2-# 10878612
60 Allt G. Lawrenson J.G. Pericytes: Cell biology and pathology. Cells Tissues Organs 2001 169 1 1 11 10.1159/000047855 11340256
61 Aguilera K.Y. Brekken R.A. Recruitment and retention: Factors that affect pericyte migration. Cell. Mol. Life Sci. 2014 71 2 299 309 10.1007/s00018-013-1432-z 23912898
62 Bell R.D. Winkler E.A. Sagare A.P. Singh I. LaRue B. Deane R. Zlokovic B.V. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010 68 3 409 427 10.1016/j.neuron.2010.09.043 21040844
63 Shepro D. Morel N.M.L. Pericyte physiology. FASEB J. 1993 7 11 1031 1038 10.1096/fasebj.7.11.8370472 8370472
64 Nakagawa S. Deli M.A. Kawaguchi H. Shimizudani T. Shimono T. Kittel Á. Tanaka K. Niwa M. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem. Int. 2009 54 3-4 253 263 10.1016/j.neuint.2008.12.002 19111869
65 Wang S. Cao C. Chen Z. Bankaitis V. Tzima E. Sheibani N. Burridge K. Pericytes regulate vascular basement membrane remodeling and govern neutrophil extravasation during inflammation. PLoS One 2012 7 9 e45499 10.1371/journal.pone.0045499 23029055
66 Nichols N.R. Day J.R. Laping N.J. Johnson S.A. Finch C.E. GFAP mRNA increases with age in rat and human brain. Neurobiol. Aging 1993 14 5 421 429 10.1016/0197-4580(93)90100-P 8247224
67 Oberheim N.A. Takano T. Han X. He W. Lin J.H.C. Wang F. Xu Q. Wyatt J.D. Pilcher W. Ojemann J.G. Ransom B.R. Goldman S.A. Nedergaard M. Uniquely hominid features of adult human astrocytes. J. Neurosci. 2009 29 10 3276 3287 10.1523/JNEUROSCI.4707-08.2009 19279265
68 Bazargani N. Attwell D. Astrocyte calcium signaling: The third wave. Nat. Neurosci. 2016 19 2 182 189 10.1038/nn.4201 26814587
69 Mathiisen T.M. Lehre K.P. Danbolt N.C. Ottersen O.P. The perivascular astroglial sheath provides a complete covering of the brain microvessels: An electron microscopic 3D reconstruction. Glia 2010 58 9 1094 1103 10.1002/glia.20990 20468051
70 Gee J.R. Keller J.N. Astrocytes: Regulation of brain homeostasis via apolipoprotein E. Int. J. Biochem. Cell Biol. 2005 37 6 1145 1150 10.1016/j.biocel.2004.10.004 15778078
71 Friede R. Quantitative share of the glia in development of the cortex. Acta Anat. 1954 20 3 290 296 10.1159/000140905 13137775
72 Pelvig D.P. Pakkenberg H. Stark A.K. Pakkenberg B. Neocortical glial cell numbers in human brains. Neurobiol. Aging 2008 29 11 1754 1762 10.1016/j.neurobiolaging.2007.04.013 17544173
73 Herculano-Houzel S. The glia/neuron ratio: How it varies uniformly across brain structures and species and what that means for brain physiology and evolution. Glia 2014 62 9 1377 1391 10.1002/glia.22683 24807023
74 Nagy J.I. Patel D. Ochalski P.A.Y. Stelmack G.L. Connexin30 in rodent, cat and human brain: Selective expression in gray matter astrocytes, co-localization with connexin43 at gap junctions and late developmental appearance. Neuroscience 1999 88 2 447 468 10.1016/S0306-4522(98)00191-2 10197766
75 Gaillard P.J. Voorwinden L.H. Nielsen J.L. Ivanov A. Atsumi R. Engman H. Ringbom C. de Boer A.G. Breimer D.D. Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur. J. Pharm. Sci. 2001 12 3 215 222 10.1016/S0928-0987(00)00123-8 11113640
76 Yung W.K. Luna M. Borit A. Vimentin and glial fibrillary acidic protein in human brain tumors. J. Neurooncol. 1985 3 1 35 38 10.1007/BF00165169 3889231
77 Sun D. Lytle C. O’Donnell M.E. IL-6 secreted by astroglial cells regulates Na-K-Cl cotransport in brain microvessel endothelial cells. Am. J. Physiol. Cell Physiol. 1997 272 6 C1829 C1835 10.1152/ajpcell.1997.272.6.C1829 9227411
78 Sobue K. Yamamoto N. Yoneda K. Hodgson M.E. Yamashiro K. Tsuruoka N. Tsuda T. Katsuya H. Miura Y. Asai K. Kato T. Induction of blood-brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors. Neurosci. Res. 1999 35 2 155 164 10.1016/S0168-0102(99)00079-6 10616919
79 Tran N.D. Correale J. Schreiber S.S. Fisher M. Transforming growth factor-β mediates astrocyte-specific regulation of brain endothelial anticoagulant factors. Stroke 1999 30 8 1671 1678 10.1161/01.STR.30.8.1671 10436120
80 Kim K.K. Adelstein R.S. Kawamoto S. Identification of neuronal nuclei (NeuN) as Fox-3, a new member of the Fox-1 gene family of splicing factors. J. Biol. Chem. 2009 284 45 31052 31061 10.1074/jbc.M109.052969 19713214
81 Katsetos C.D. Herman M.M. Mörk S.J. Class III β‐tubulin in human development and cancer. Cell Motil. Cytoskeleton 2003 55 2 77 96 10.1002/cm.10116 12740870
82 Aihara M. Ishii S. Kume K. Shimizu T. Interaction between neurone and microglia mediated by platelet‐activating factor. Genes Cells 2000 5 5 397 406 10.1046/j.1365-2443.2000.00333.x 10886367
83 Tan Y.L. Yuan Y. Tian L. Microglial regional heterogeneity and its role in the brain. Mol. Psychiatry 2020 25 2 351 367 10.1038/s41380-019-0609-8 31772305
84 Biber K. Owens T. Boddeke E. What is microglia neurotoxicity (Not)? Glia 2014 62 6 841 854 10.1002/glia.22654 24590682
85 Lai A.Y. Dhami K.S. Dibal C.D. Todd K.G. Neonatal rat microglia derived from different brain regions have distinct activation responses. Neuron Glia Biol. 2011 7 1 5 16 10.1017/S1740925X12000154 22857737
86 Katsumoto A. Lu H. Miranda A.S. Ransohoff R.M. Ontogeny and functions of central nervous system macrophages. J. Immunol. 2014 193 6 2615 2621 10.4049/jimmunol.1400716 25193935
87 Ajami B. Bennett J.L. Krieger C. Tetzlaff W. Rossi F.M.V. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci. 2007 10 12 1538 1543 10.1038/nn2014 18026097
88 Kierdorf K. Erny D. Goldmann T. Sander V. Schulz C. Perdiguero E.G. Wieghofer P. Heinrich A. Riemke P. Hölscher C. Müller D.N. Luckow B. Brocker T. Debowski K. Fritz G. Opdenakker G. Diefenbach A. Biber K. Heikenwalder M. Geissmann F. Rosenbauer F. Prinz M. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat. Neurosci. 2013 16 3 273 280 10.1038/nn.3318 23334579
89 Davalos D. Grutzendler J. Yang G. Kim J.V. Zuo Y. Jung S. Littman D.R. Dustin M.L. Gan W.B. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 2005 8 6 752 758 10.1038/nn1472 15895084
90 Thurgur H. Pinteaux E. Microglia in the neurovascular nnit: Blood-brain barrier-microglia interactions after central nervous system disorders. Neuroscience 2019 405 55 67 10.1016/j.neuroscience.2018.06.046 31007172
91 Grossmann R. Stence N. Carr J. Fuller L. Waite M. Dailey M.E. Juxtavascular microglia migrate along brain microvessels following activation during early postnatal development. Glia 2002 37 3 229 240 10.1002/glia.10031 11857681
92 Kabba J.A. Xu Y. Christian H. Ruan W. Chenai K. Xiang Y. Zhang L. Saavedra J.M. Pang T. Microglia: housekeeper of the central nervous system. Cell. Mol. Neurobiol. 2018 38 1 53 71 10.1007/s10571-017-0504-2 28534246
93 Ito D. Imai Y. Ohsawa K. Nakajima K. Fukuuchi Y. Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res. Mol. Brain Res. 1998 57 1 1 9 10.1016/S0169-328X(98)00040-0 9630473
94 Carson M.J. Doose J.M. Melchior B. Schmid C.D. Ploix C.C. CNS immune privilege: Hiding in plain sight. Immunol. Rev. 2006 213 1 48 65 10.1111/j.1600-065X.2006.00441.x 16972896
95 Engelhardt B. Carare R.O. Bechmann I. Flügel A. Laman J.D. Weller R.O. Vascular, glial, and lymphatic immune gateways of the central nervous system. Acta Neuropathol. 2016 132 3 317 338 10.1007/s00401-016-1606-5 27522506
96 Nishioku T. Matsumoto J. Dohgu S. Sumi N. Miyao K. Takata F. Shuto H. Yamauchi A. Kataoka Y. Tumor necrosis factor-α mediates the blood-brain barrier dysfunction induced by activated microglia in mouse brain microvascular endothelial cells. J. Pharmacol. Sci. 2010 112 2 251 254 10.1254/jphs.09292SC 20118615
97 Yang Y. Salayandia V.M. Thompson J.F. Yang L.Y. Estrada E.Y. Yang Y. Attenuation of acute stroke injury in rat brain by minocycline promotes blood-brain barrier remodeling and alternative microglia/macrophage activation during recovery. J. Neuroinflammation 2015 12 1 26 10.1186/s12974-015-0245-4 25889169
98 Nakajima K. Tohyama Y. Maeda S. Kohsaka S. Kurihara T. Neuronal regulation by which microglia enhance the production of neurotrophic factors for GABAergic, catecholaminergic, and cholinergic neurons. Neurochem. Int. 2007 50 6 807 820 10.1016/j.neuint.2007.02.006 17459525
99 Abbott N.J. Anatomy and physiology of the blood - brain barriers. Drug delivery to the brain AAPS Advances in the Pharmaceutical Sciences Series. Hammarlund-Udenaes M. de Lange E. Thorne R. New York, NY Springer 2014 10.1007/978-1-4614-9105-7_1
100 Helms H.C. Abbott N.J. Burek M. Cecchelli R. Couraud P.O. Deli M.A. Förster C. Galla H.J. Romero I.A. Shusta E.V. Stebbins M.J. Vandenhaute E. Weksler B. Brodin B. In vitro models of the blood-brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use. J. Cereb. Blood Flow Metab. 2016 36 5 862 890 10.1177/0271678X16630991 26868179
101 Annunziata P. Cioni C. Toneatto S. Paccagnini E. HIV-1 gp120 increases the permeability of rat brain endothelium cultures by a mechanism involving substance P. AIDS 1998 12 18 2377 2385 10.1097/00002030-199818000-00006 9875575
102 Chen Y. McCarron R.M. Azzam N. Bembry J. Reutzler C. Lenz F.A. Spatz M. Endothelin-1 and nitric oxide affect human cerebromicrovascular endothelial responses and signal transduction. Acta Neurochir. Suppl. 2000 76 131 135 10.1007/978-3-7091-6346-7_27 11449992
103 Št’astný F. Škultétyová I. Pliss L. Ježová D. Quinolinic acid enhances permeability of rat brain microvessels to plasma albumin. Brain Res. Bull. 2000 53 4 415 420 10.1016/S0361-9230(00)00368-3 11136997
104 Chapouly C. Tadesse Argaw A. Horng S. Castro K. Zhang J. Asp L. Loo H. Laitman B.M. Mariani J.N. Straus Farber R. Zaslavsky E. Nudelman G. Raine C.S. John G.R. Astrocytic TYMP and VEGFA drive blood-brain barrier opening in inflammatory central nervous system lesions. Brain 2015 138 6 1548 1567 10.1093/brain/awv077 25805644
105 Yang R. Liu W. Miao L. Yang X. Fu J. Dou B. Cai A. Zong X. Tan C. Chen H. Wang X. Induction of VEGFA and Snail-1 by meningitic Escherichia coli mediates disruption of the blood-brain barrier. Oncotarget 2016 7 39 63839 63855 10.18632/oncotarget.11696 27588479
106 Argaw A.T. Gurfein B.T. Zhang Y. Zameer A. John G.R. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc. Natl. Acad. Sci. 2009 106 6 1977 1982 10.1073/pnas.0808698106 19174516
107 Argaw A.T. Asp L. Zhang J. Navrazhina K. Pham T. Mariani J.N. Mahase S. Dutta D.J. Seto J. Kramer E.G. Ferrara N. Sofroniew M.V. John G.R. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J. Clin. Invest. 2012 122 7 2454 2468 10.1172/JCI60842 22653056
108 Carmen-Orozco R.P. Dávila-Villacorta D.G. Cauna Y. Bernal-Teran E.G. Bitterfeld L. Sutherland G.L. Chile N. Céliz R.H. Ferrufino-Schmidt M.C. Gavídia C.M. Sterling C.R. García H.H. Gilman R.H. Verástegui M.R. Blood-brain barrier disruption and angiogenesis in a rat model for neurocysticercosis. J. Neurosci. Res. 2019 97 2 137 148 10.1002/jnr.24335 30315659
109 Corada M. Mariotti M. Thurston G. Smith K. Kunkel R. Brockhaus M. Lampugnani M.G. Martin-Padura I. Stoppacciaro A. Ruco L. McDonald D.M. Ward P.A. Dejana E. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc. Natl. Acad. Sci. 1999 96 17 9815 9820 10.1073/pnas.96.17.9815 10449777
110 Vestweber D. VE-Cadherin. Arterioscler. Thromb. Vasc. Biol. 2008 28 2 223 232 10.1161/ATVBAHA.107.158014 18162609
111 Coureuil M. Mikaty G. Miller F. Lécuyer H. Bernard C. Bourdoulous S. Meningococcal type IV pili recruit the polarity complex to cross the brain endothelium. Science 2009 325 5936 83 87 10.1126/science.1173196 19520910
112 Song L. Ge S. Pachter J.S. Caveolin-1 regulates expression of junction-associated proteins in brain microvascular endothelial cells. Blood 2007 109 4 1515 1523 10.1182/blood-2006-07-034009 17023578
113 Nusrat A. Parkos C.A. Verkade P. Foley C.S. Liang T.W. Innis-Whitehouse W. Eastburn K.K. Madara J.L. Tight junctions are membrane microdomains. J. Cell Sci. 2000 113 10 1771 1781 10.1242/jcs.113.10.1771 10769208
114 Alves J.L. Blood-brain barrier and traumatic brain injury. J. Neurosci. Res. 2014 92 2 141 147 10.1002/jnr.23300 24327344
115 Tuttolomondo A. Di Raimondo D. di Sciacca R. Pinto A. Licata G. Inflammatory cytokines in acute ischemic stroke. Curr. Pharm. Des. 2008 14 33 3574 3589 10.2174/138161208786848739 19075734
116 Song L. Pachter J.S. Monocyte chemoattractant protein-1 alters expression of tight junction-associated proteins in brain microvascular endothelial cells. Microvasc. Res. 2004 67 1 78 89 10.1016/j.mvr.2003.07.001 14709405
117 Stamatovic S.M. Keep R.F. Kunkel S.L. Andjelkovic A.V. Potential role of MCP-1 in endothelial cell tight junction ‘opening’: Signaling via Rho and Rho kinase. J. Cell Sci. 2003 116 22 4615 4628 10.1242/jcs.00755 14576355
118 dos Santos A.C. Barsante M.M. Esteves Arantes R.M. Bernard C.C.A. Teixeira M.M. Carvalho-Tavares J. CCL2 and CCL5 mediate leukocyte adhesion in experimental autoimmune encephalomyelitis-an intravital microscopy study. J. Neuroimmunol. 2005 162 1-2 122 129 10.1016/j.jneuroim.2005.01.020 15833367
119 Chui R. Dorovini-Zis K. Regulation of CCL2 and CCL3 expression in human brain endothelial cells by cytokines and lipopolysaccharide. J. Neuroinflammation 2010 7 1 1 10.1186/1742-2094-7-1 20047691
120 Glabinski A.R. Balasingam V. Tani M. Kunkel S.L. Strieter R.M. Yong V.W. Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain. J. Immunol. 1996 156 11 4363 4368 10.4049/jimmunol.156.11.4363 8666808
121 Takeshita Y. Ransohoff R.M. Inflammatory cell trafficking across the blood-brain barrier: Chemokine regulation and in vitro models. Immunol. Rev. 2012 248 1 228 239 10.1111/j.1600-065X.2012.01127.x 22725965
122 Sivandzade F. Cucullo L. In-vitro blood-brain barrier modeling: A review of modern and fast-advancing technologies. J. Cereb. Blood Flow Metab. 2018 38 10 1667 1681 10.1177/0271678X18788769 30058456
123 Andjelkovic A.V. Stamatovic S.M. Phillips C.M. Martinez-Revollar G. Keep R.F. Modeling blood-brain barrier pathology in cerebrovascular disease in vitro: Current and future paradigms. Fluids Barriers CNS 2020 17 1 44 10.1186/s12987-020-00202-7 32677965
124 Bhalerao A. Sivandzade F. Archie S.R. Chowdhury E.A. Noorani B. Cucullo L. In vitro modeling of the neurovascular unit: Advances in the field. Fluids Barriers CNS 2020 17 1 22 10.1186/s12987-020-00183-7 32178700
125 Hajal C. Campisi M. Mattu C. Chiono V. Kamm R.D. In vitro models of molecular and nano-particle transport across the blood-brain barrier. Biomicrofluidics 2018 12 4 042213 10.1063/1.5027118 29887937
126 Bagchi S. Chhibber T. Lahooti B. Verma A. Borse V. Jayant R.D. In-vitro blood-brain barrier models for drug screening and permeation studies: an overview. Drug Des. Devel. Ther. 2019 13 3591 3605 10.2147/DDDT.S218708 31695329
127 Gastfriend B.D. Palecek S.P. Shusta E.V. Modeling the blood-brain barrier: Beyond the endothelial cells. Curr. Opin. Biomed. Eng. 2018 5 6 12 10.1016/j.cobme.2017.11.002 29915815
128 Herland A. van der Meer A.D. FitzGerald E.A. Park T.E. Sleeboom J.J.F. Ingber D.E. Distinct contributions of astrocytes and pericytes to neuroinflammation identified in a 3D human blood-brain barrier on a chip. PLoS One 2016 11 3 e0150360 10.1371/journal.pone.0150360 26930059
129 Santaguida S. Janigro D. Hossain M. Oby E. Rapp E. Cucullo L. Side by side comparison between dynamic versus static models of blood-brain barrier in vitro: A permeability study. Brain Res. 2006 1109 1 1 13 10.1016/j.brainres.2006.06.027 16857178
130 Kaisar M.A. Sajja R.K. Prasad S. Abhyankar V.V. Liles T. Cucullo L. New experimental models of the blood-brain barrier for CNS drug discovery. Expert Opin. Drug Discov. 2017 12 1 89 103 10.1080/17460441.2017.1253676 27782770
131 Jiang L. Li S. Zheng J. Li Y. Huang H. Recent progress in microfluidic models of the blood-brain barrier. Micromachines 2019 10 6 375 10.3390/mi10060375 31195652
132 Naik P. Cucullo L. In vitro blood-brain barrier models: Current and perspective technologies. J. Pharm. Sci. 2012 101 4 1337 1354 10.1002/jps.23022 22213383
133 Roberts L.M. Black D.S. Raman C. Woodford K. Zhou M. Haggerty J.E. Yan A.T. Cwirla S.E. Grindstaff K.K. Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation. Neuroscience 2008 155 2 423 438 10.1016/j.neuroscience.2008.06.015 18619525
134 Ghosh C. Gonzalez-Martinez J. Hossain M. Cucullo L. Fazio V. Janigro D. Marchi N. Pattern of P450 expression at the human blood-brain barrier: Roles of epileptic condition and laminar flow. Epilepsia 2010 51 8 1408 1417 10.1111/j.1528-1167.2009.02428.x 20074231
135 Ghosh C. Puvenna V. Gonzalez-Martinez J. Janigro D. Marchi N. Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: A synergistic role in neurological diseases. Curr. Drug Metab. 2011 12 8 742 749 10.2174/138920011798357051 21568937
136 Dauchy S. Dutheil F. Weaver R.J. Chassoux F. Daumas-Duport C. Couraud P.O. Scherrmann J.M. De Waziers I. Declèves X. ABC transporters, cytochromes P450 and their main transcription factors: Expression at the human blood-brain barrier. J. Neurochem. 2008 107 6 1518 1528 10.1111/j.1471-4159.2008.05720.x 19094056
137 Abbott N.J. Romero I.A. Transporting therapeutics across the blood-brain barrier. Mol. Med. Today 1996 2 3 106 113 10.1016/1357-4310(96)88720-X 8796867
138 Ghazanfari F.A. Stewart R.R. Characteristics of endothelial cells derived from the blood-brain barrier and of astrocytes in culture. Brain Res. 2001 890 1 49 65 10.1016/S0006-8993(00)03053-5 11164768
139 Kido Y. Tamai I. Nakanishi T. Kagami T. Hirosawa I. Sai Y. Tsuji A. Evaluation of blood-brain barrier transporters by co-culture of brain capillary endothelial cells with astrocytes. Drug Metab. Pharmacokinet. 2002 17 1 34 41 10.2133/dmpk.17.34 15618650
140 Lindroos B. Aho K.L. Kuokkanen H. Räty S. Huhtala H. Lemponen R. Yli-Harja O. Suuronen R. Miettinen S. Differential gene expression in adipose stem cells cultured in allogeneic human serum versus fetal bovine serum. Tissue Eng. Part A 2010 16 7 2281 2294 10.1089/ten.tea.2009.0621 20184435
141 Jancic C. Chuluyan H.E. Morelli A. Larregina A. Kolkowski E. Saracco M. Barboza M. Leiva W.S. Fainboim L. Interactions of dendritic cells with fibronectin and endothelial cells. Immunology 1998 95 2 283 290 10.1046/j.1365-2567.1998.00586.x 9824488
142 Syvänen S. Lindhe Ö. Palner M. Kornum B.R. Rahman O. Långström B. Knudsen G.M. Hammarlund-Udenaes M. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab. Dispos. 2009 37 3 635 643 10.1124/dmd.108.024745 19047468
143 Uchida Y. Ohtsuki S. Katsukura Y. Ikeda C. Suzuki T. Kamiie J. Terasaki T. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem. 2011 117 2 333 345 10.1111/j.1471-4159.2011.07208.x 21291474
144 Warren M.S. Zerangue N. Woodford K. Roberts L.M. Tate E.H. Feng B. Li C. Feuerstein T.J. Gibbs J. Smith B. de Morais S.M. Dower W.J. Koller K.J. Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol. Res. 2009 59 6 404 413 10.1016/j.phrs.2009.02.007 19429473
145 Löscher W. Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 2005 76 1 22 76 10.1016/j.pneurobio.2005.04.006 16011870
146 Bernas M.J. Cardoso F.L. Daley S.K. Weinand M.E. Campos A.R. Ferreira A.J.G. Hoying J.B. Witte M.H. Brites D. Persidsky Y. Ramirez S.H. Brito M.A. Establishment of primary cultures of human brain microvascular endothelial cells to provide an in vitro cellular model of the blood-brain barrier. Nat. Protoc. 2010 5 7 1265 1272 10.1038/nprot.2010.76 20595955
147 Weksler B.B. Subileau E.A. Perrière N. Charneau P. Holloway K. Leveque M. Tricoire-Leignel H. Nicotra A. Bourdoulous S. Turowski P. Male D.K. Roux F. Greenwood J. Romero I.A. Couraud P.O. Blood‐brain barrier‐specific properties of a human adult brain endothelial cell line. FASEB J. 2005 19 13 1872 1874 10.1096/fj.04-3458fje 16141364
148 Marroni M. Kight K.M. Hossain M. Cucullo L. Desai S.Y. Janigro D. Dynamic In vitro model of the blood-brain barrier: biology and research protocols. Totowa, NJ Humana Press 2003 419 434 10.1385/1-59259-419-0:419
149 Deli M.A. Blood-brain barrier models BT - Handbook of neurochemistry and molecular neurobiology: neural membranes and transport. Boston, MA Springer US 2007 29 55 10.1007/978-0-387-30380-2_2
150 Helms H.C. Waagepetersen H.S. Nielsen C.U. Brodin B. Paracellular tightness and claudin-5 expression is increased in the BCEC/astrocyte blood-brain barrier model by increasing media buffer capacity during growth. AAPS J. 2010 12 4 759 770 10.1208/s12248-010-9237-6 20967520
151 Patabendige A. Skinner R.A. Abbott N.J. Establishment of a simplified in vitro porcine blood-brain barrier model with high transendothelial electrical resistance. Brain Res. 2013 1521 1 15 10.1016/j.brainres.2012.06.057 22789905
152 Idris F. Muharram H.S. Zaini Z. Diah S. Establishment of murine in vitro blood-brain barrier models using immortalized cell lines: Co-cultures of brain endothelial cells, astrocytes, and neurons. bioRxiv 2018 435990 10.1101/435990
153 Cucullo L. Hossain M. Rapp E. Manders T. Marchi N. Janigro D. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 2007 48 3 505 516 10.1111/j.1528-1167.2006.00960.x 17326793
154 Ghosh C. Hossain M. Solanki J. Najm I.M. Marchi N. Janigro D. Overexpression of pregnane X and glucocorticoid receptors and the regulation of cytochrome P450 in human epileptic brain endothelial cells. Epilepsia 2017 58 4 576 585 10.1111/epi.13703 28199000
155 Labus J. Häckel S. Lucka L. Danker K. Interleukin-1β induces an inflammatory response and the breakdown of the endothelial cell layer in an improved human THBMEC-based in vitro blood-brain barrier model. J. Neurosci. Methods 2014 228 35 45 10.1016/j.jneumeth.2014.03.002 24631939
156 Srinivasan B. Kolli A.R. Esch M.B. Abaci H.E. Shuler M.L. Hickman J.J. TEER measurement techniques for in vitro barrier model systems. SLAS Technol. 2015 20 2 107 126 10.1177/2211068214561025 25586998
157 Crone C. Olesen S.P. Electrical resistance of brain microvascular endothelium. Brain Res. 1982 241 1 49 55 10.1016/0006-8993(82)91227-6 6980688
158 Butt A.M. Jones H.C. Abbott N.J. Electrical resistance across the blood‐brain barrier in anaesthetized rats: A developmental study. J. Physiol. 1990 429 1 47 62 10.1113/jphysiol.1990.sp018243 2277354
159 Crone C. Christensen O. Electrical resistance of a capillary endothelium. J. Gen. Physiol. 1981 77 4 349 371 10.1085/jgp.77.4.349 7241087
160 Eigenmann D.E. Xue G. Kim K.S. Moses A.V. Hamburger M. Oufir M. Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood-brain barrier model for drug permeability studies. Fluids Barriers CNS 2013 10 1 33 10.1186/2045-8118-10-33 24262108
161 Veszelka S. Tóth A. Walter F.R. Tóth A.E. Gróf I. Mészáros M. Bocsik A. Hellinger É. Vastag M. Rákhely G. Deli M.A. Comparison of a rat primary cell-based blood-brain barrier model with epithelial and brain endothelial cell lines : Gene expression and drug transport. Front. Mol. Neurosci. 2018 11 166 10.3389/fnmol.2018.00166 29872378
162 Maherally Z. Fillmore H.L. Tan S.L. Tan S.F. Jassam S.A. Quack F.I. Hatherell K.E. Pilkington G.J. Real‐time acquisition of transendothelial electrical resistance in an all‐human, in vitro, 3‐dimensional, blood‐brain barrier model exemplifies tight‐junction integrity. FASEB J. 2018 32 1 168 182 10.1096/fj.201700162R 28883042
163 Elbakary B. Badhan R.K.S. A dynamic perfusion based blood-brain barrier model for cytotoxicity testing and drug permeation. Sci. Rep. 2020 10 1 3788 10.1038/s41598-020-60689-w 32123236
164 Förster C. Burek M. Romero I.A. Weksler B. Couraud P.O. Drenckhahn D. Differential effects of hydrocortisone and TNFα on tight junction proteins in an in vitro model of the human blood-brain barrier. J. Physiol. 2008 586 7 1937 1949 10.1113/jphysiol.2007.146852 18258663
165 Stone N.L. England T.J. O’Sullivan S.E. A novel transwell blood brain barrier model using primary human cells. Front. Cell. Neurosci. 2019 13 230 10.3389/fncel.2019.00230 31244605
166 Cucullo L. Marchi N. Hossain M. Janigro D. A dynamic in vitro BBB model for the study of immune cell trafficking into the central nervous system. J. Cereb. Blood Flow Metab. 2011 31 2 767 777 10.1038/jcbfm.2010.162 20842162
167 Prudhomme J.G. Sherman I.W. Land K.M. Moses A.V. Stenglein S. Nelson J.A. Studies of Plasmodium falciparum cytoadherence using immortalized human brain capillary endothelial cells. Int. J. Parasitol. 1996 26 6 647 655 10.1016/0020-7519(96)00027-6 8875310
168 Sano Y. Kashiwamura Y. Abe M. Dieu L.H. Huwyler J. Shimizu F. Haruki H. Maeda T. Saito K. Tasaki A. Kanda T. Stable human brain microvascular endothelial cell line retaining its barrier‐specific nature independent of the passage number. Clin. Exp. Neuroimmunol. 2013 4 1 92 103 10.1111/cen3.12001
169 Watson P.M.D. Paterson J.C. Thom G. Ginman U. Lundquist S. Webster C.I. Modelling the endothelial blood-CNS barriers: A method for the production of robust in vitromodels of the rat blood-brain barrier and blood-spinal cord barrier. BMC Neurosci. 2013 14 1 59 10.1186/1471-2202-14-59 23773766
170 Booth R. Kim H. Characterization of a microfluidic in vitro model of the blood-brain barrier (μBBB). Lab Chip 2012 12 10 1784 1792 10.1039/c2lc40094d 22422217
171 Poller B. Gutmann H. Krähenbühl S. Weksler B. Romero I. Couraud P.O. Tuffin G. Drewe J. Huwyler J. The human brain endothelial cell line hCMEC/D3 as a human blood‐brain barrier model for drug transport studies. J. Neurochem. 2008 107 5 1358 1368 10.1111/j.1471-4159.2008.05730.x 19013850
172 Camós S. Mallolas J. Experimental models for assaying microvascular endothelial cell pathophysiology in stroke. Molecules 2010 15 12 9104 9134 10.3390/molecules15129104 21150829
173 Even-Ram S. Yamada K.M. Cell migration in 3D matrix. Curr. Opin. Cell Biol. 2005 17 5 524 532 10.1016/j.ceb.2005.08.015 16112853
174 Cecchelli R. Dehouck B. Descamps L. Fenart L. Buée-Scherrer V. Duhem C. Lundquist S. Rentfel M. Torpier G. Dehouck M.P. In vitro model for evaluating drug transport across the blood-brain barrier. Adv. Drug Deliv. Rev. 1999 36 2-3 165 178 10.1016/S0169-409X(98)00083-0 10837714
175 Wuest D.M. Wing A.M. Lee K.H. Membrane configuration optimization for a murine in vitro blood-brain barrier model. J. Neurosci. Methods 2013 212 2 211 221 10.1016/j.jneumeth.2012.10.016 23131353
176 Chiu J.J. Chen L.J. Chang S.F. Lee P.L. Lee C.I. Tsai M.C. Lee D.Y. Hsieh H.P. Usami S. Chien S. Shear stress inhibits smooth muscle cell-induced inflammatory gene expression in endothelial cells: role of NF-kappaB. Arterioscler. Thromb. Vasc. Biol. 2005 25 5 963 969 10.1161/01.ATV.0000159703.43374.19 15718492
177 Desai S.Y. Marroni M. Cucullo L. Krizanac-Bengez L. Mayberg M.R. Hossain M.T. Grant G.G. Janigro D. Mechanisms of endothelial survival under shear stress. Endothelium 2002 9 2 89 102 10.1080/10623320212004 12200960
178 DeStefano J.G. Williams A. Wnorowski A. Yimam N. Searson P.C. Wong A.D. Real-time quantification of endothelial response to shear stress and vascular modulators. Integr. Biol. 2017 9 4 362 374 10.1039/C7IB00023E 28345713
179 Partyka P.P. Godsey G.A. Galie J.R. Kosciuk M.C. Acharya N.K. Nagele R.G. Galie P.A. Mechanical stress regulates transport in a compliant 3D model of the blood-brain barrier. Biomaterials 2017 115 30 39 10.1016/j.biomaterials.2016.11.012 27886553
180 Kaya M. Ahishali B. Assessment of permeability in barrier type of endothelium in brain using tracers: Evans blue, sodium fluorescein, and horseradish peroxidase. Permeability Barrier: Methods and Protocols, Methods in Molecular Biology. Turksen K. Humana Press 2011 369 382 10.1007/978-1-61779-191-8_25
181 Wilhelm I. Fazakas C. Krizbai I. In vitro models of the blood-brain barrier. Acta Neurobiol. Exp. 2011 71 1 113 128 10.55782/ane-2011-1828 21499332
182 Obermeier B. Daneman R. Ransohoff R.M. Development, maintenance and disruption of the blood-brain barrier. Nat. Med. 2013 19 12 1584 1596 10.1038/nm.3407 24309662
183 Czupalla C.J. Liebner S. Devraj K. In vitro models of the blood-brain barrier. Cerebral angiogenesis methods in molecular biology. Milner R. New York, NY Humana Press 2014 415 437 10.1007/978-1-4939-0320-7_34
184 Rahman N.A. Sharudin A. Diah S. Muharram S.H. Serotyping of Brunei pneumococcal clinical strains and the investigation of their capability to adhere and invade a brain endothelium model. Microb. Pathog. 2017 110 352 358 10.1016/j.micpath.2017.07.021 28711510
185 Williams-Medina A. Deblock M. Janigro D. In vitro models of the blood-brain barrier: Tools in translational medicine. Front. Med. Technol. 2021 2 623950 10.3389/fmedt.2020.623950 35047899
186 Alimonti J.B. Ribecco-Lutkiewicz M. Sodja C. Jezierski A. Stanimirovic D.B. Liu Q. Haqqani A.S. Conlan W. Bani-Yaghoub M. Zika virus crosses an in vitro human blood brain barrier model. Fluids Barriers CNS 2018 15 1 15 10.1186/s12987-018-0100-y 29759080
187 Ribecco-Lutkiewicz M. Sodja C. Haukenfrers J. Haqqani A.S. Ly D. Zachar P. Baumann E. Ball M. Huang J. Rukhlova M. Martina M. Liu Q. Stanimirovic D. Jezierski A. Bani-Yaghoub M. A novel human induced pluripotent stem cell blood-brain barrier model: Applicability to study antibody-triggered receptor-mediated transcytosis. Sci. Rep. 2018 8 1 1873 10.1038/s41598-018-19522-8 29382846
188 Wong M.K. Gotlieb A.I. Endothelial cell monolayer integrity. I. Characterization of dense peripheral band of microfilaments. Arteriosclerosis 1986 6 2 212 219 10.1161/01.ATV.6.2.212 3954675
189 Kazakoff P.W. McGuire T.R. Hoie E.B. Cano M. Iversen P.L. An in vitro model for endothelial permeability: Assessment of monolayer integrity. Vitr Cell Dev Biol - Anim 1995 31 11 846 852
190 Cooray H.C. Blackmore C.G. Maskell L. Barrand M.A. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002 13 16 2059 2063 10.1097/00001756-200211150-00014 12438926
191 Zhang W. Mojsilovic-Petrovic J. Andrade M.F. Zhang H. Ball M. Stanimirovic D.B. Expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J. 2003 17 14 1 24 10.1096/fj.02-1131fje 12522106
192 Kido Y. Tamai I. Okamoto M. Suzuki F. Tsuji A. Functional clarification of MCT1-mediated transport of monocarboxylic acids at the blood-brain barrier using in vitro cultured cells and in vivo BUI studies. Pharm. Res. 2000 17 1 55 62 10.1023/A:1007518525161 10714609
193 Zheng P.P. Romme E. Spek P.J. Dirven C.M.F. Willemsen R. Kros J.M. Glut1/SLC2A1 is crucial for the development of the blood‐brain barrier in vivo. Ann. Neurol. 2010 68 6 835 844 10.1002/ana.22318 21194153
194 Hersom M. Helms H.C. Pretzer N. Goldeman C. Jensen A.I. Severin G. Nielsen M.S. Holm R. Brodin B. Transferrin receptor expression and role in transendothelial transport of transferrin in cultured brain endothelial monolayers. Mol. Cell. Neurosci. 2016 76 59 67 10.1016/j.mcn.2016.08.009 27567687
195 Hayashi Y. Nomura M. Yamagishi S.I. Harada S.I. Yamashita J. Yamamoto H. Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes. Glia 1997 19 1 13 26 10.1002/(SICI)1098-1136(199701)19:1<13:AID-GLIA2>3.0.CO;2-B 8989564
196 Zhao Z. Nelson A.R. Betsholtz C. Zlokovic B.V. Establishment and dysfunction of the blood-brain barrier. Cell 2015 163 5 1064 1078 10.1016/j.cell.2015.10.067 26590417
197 Bazzoni G. Dejana E. Endothelial cell-to-cell junctions: Molecular organization and role in vascular homeostasis. Physiol. Rev. 2004 84 3 869 901 10.1152/physrev.00035.2003 15269339
198 Simi A. Tsakiri N. Wang P. Rothwell N.J. Interleukin-1 and inflammatory neurodegeneration. Biochem. Soc. Trans. 2007 35 5 1122 1126 10.1042/BST0351122 17956293
199 Shaftel S.S. Griffin W.S.T. O’Banion M.K. The role of interleukin-1 in neuroinflammation and Alzheimer disease: An evolving perspective. J. Neuroinflammation 2008 5 1 7 10.1186/1742-2094-5-7 18302763
200 Lutgendorf M.A. Ippolito D.L. Mesngon M.T. Tinnemore D. Dehart M.J. Dolinsky B.M. Napolitano P.G. Effect of dexamethasone administered with magnesium sulfate on inflammation-mediated degradation of the blood-brain barrier using an in vitro model. Reprod. Sci. 2014 21 4 483 491 10.1177/1933719113503410 24077438
201 Burkert K. Moodley K. Angel C.E. Brooks A. Graham E.S. Detailed analysis of inflammatory and neuromodulatory cytokine secretion from human NT2 astrocytes using multiplex bead array. Neurochem. Int. 2012 60 6 573 580 10.1016/j.neuint.2011.09.002 21939706
202 Shigemoto-Mogami Y. Hoshikawa K. Sato K. Activated microglia disrupt the blood-brain barrier and induce chemokines and cytokines in a rat in vitro model. Front. Cell. Neurosci. 2018 12 494 10.3389/fncel.2018.00494 30618641
203 Banks W.A. Gray A.M. Erickson M.A. Salameh T.S. Damodarasamy M. Sheibani N. Meabon J.S. Wing E.E. Morofuji Y. Cook D.G. Reed M.J. Lipopolysaccharide-induced blood-brain barrier disruption: Roles of cyclooxygenase, oxidative stress, neuroinflammation, and elements of the neurovascular unit. J. Neuroinflammation 2015 12 1 223 10.1186/s12974-015-0434-1 26608623
204 Greenwood J. Howes R. Lightman S. The blood-retinal barrier in experimental autoimmune uveoretinitis. Leukocyte interactions and functional damage. Lab. Invest. 1994 70 1 39 52 8302017
205 Abadier M. Jahromi H.N. Alves C.L. Boscacci R. Vestweber D. Barnum S. Deutsch U. Engelhardt B. Lyck R. Cell surface levels of endothelial ICAM‐1 influence the transcellular or paracellular T‐cell diapedesis across the blood-brain barrier. Eur. J. Immunol. 2015 45 4 1043 1058 10.1002/eji.201445125 25545837
206 Kim K.S. Current concepts on the pathogenesis of Escherichia coli meningitis. Curr. Opin. Infect. Dis. 2012 25 3 273 278 10.1097/QCO.0b013e3283521eb0 22395761
207 Yang R.C. Qu X.Y. Xiao S.Y. Li L. Xu B.J. Fu J.Y. Lv Y.J. Amjad N. Tan C. Kim K.S. Chen H.C. Wang X.R. Meningitic Escherichia coli-induced upregulation of PDGF-B and ICAM-1 aggravates blood-brain barrier disruption and neuroinflammatory response. J. Neuroinflammation 2019 16 1 101 10.1186/s12974-019-1497-1 31092253
208 Wang X. Maruvada R. Morris A.J. Liu J.O. Wolfgang M.J. Baek D.J. Bittman R. Kim K.S. Sphingosine 1-phosphate activation of EGFR as a novel target for meningitic Escherichia coli penetration of the blood-brain barrier. PLoS Pathog. 2016 12 10 e1005926 10.1371/journal.ppat.1005926 27711202
209 Iovino F. Orihuela C.J. Moorlag H.E. Molema G. Bijlsma J.J.E. Interactions between blood-borne Streptococcus pneumoniae and the blood-brain barrier preceding meningitis. PLoS One 2013 8 7 e68408 10.1371/journal.pone.0068408 23874613
210 Orihuela C.J. Mahdavi J. Thornton J. Mann B. Wooldridge K.G. Abouseada N. Oldfield N.J. Self T. Ala’Aldeen D.A.A. Tuomanen E.I. Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models. J. Clin. Invest. 2009 119 6 1638 1646 10.1172/JCI36759 19436113
211 Henderson B. Nair S. Pallas J. Williams M.A. Fibronectin: A multidomain host adhesin targeted by bacterial fibronectin-binding proteins. FEMS Microbiol. Rev. 2011 35 1 147 200 10.1111/j.1574-6976.2010.00243.x 20695902
212 Kim B.J. Bee O.B. McDonagh M.A. Stebbins M.J. Palecek S.P. Doran K.S. Shusta E.V. Modeling group B streptococcus and blood-brain barrier interaction by using induced pluripotent stem cell-derived brain endothelial cells. MSphere 2017 2 6 e00398 e17 10.1128/mSphere.00398-17 29104935
213 Mu R. Kim B.J. Paco C. Del Rosario Y. Courtney H.S. Doran K.S. Identification of a group B streptococcal fibronectin binding protein, SfbA, that contributes to invasion of brain endothelium and development of meningitis. Infect. Immun. 2014 82 6 2276 2286 10.1128/IAI.01559-13 24643538
214 Ferguson M.C. Saul S. Fragkoudis R. Weisheit S. Cox J. Patabendige A. Sherwood K. Watson M. Merits A. Fazakerley J.K. Ability of the encephalitic arbovirus Semliki Forest virus to cross the blood-brain barrier is determined by the charge of the E2 glycoprotein. J. Virol. 2015 89 15 7536 7549 10.1128/JVI.03645-14 25972559
215 Bourgonje A.R. Abdulle A.E. Timens W. Hillebrands J.L. Navis G.J. Gordijn S.J. Bolling M.C. Dijkstra G. Voors A.A. Osterhaus A.D.M.E. van der Voort P.H.J. Mulder D.J. van Goor H. Angiotensin‐converting enzyme 2 (ACE2), SARS‐COV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19). J. Pathol. 2020 251 3 228 248 10.1002/path.5471 32418199
216 Doobay M.F. Talman L.S. Obr T.D. Tian X. Davisson R.L. Lazartigues E. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007 292 1 R373 R381 10.1152/ajpregu.00292.2006 16946085
217 Hamming I. Timens W. Bulthuis M.L.C. Lely A.T. Navis G.J. van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004 203 2 631 637 10.1002/path.1570 15141377
218 Solomon I.H. Normandin E. Bhattacharyya S. Mukerji S.S. Keller K. Ali A.S. Adams G. Hornick J.L. Padera R.F. Jr Sabeti P. Neuropathological features of COVID-19. N. Engl. J. Med. 2020 383 10 989 992 10.1056/NEJMc2019373 32530583
219 Wang Y. Cao Y. Mangalam A.K. Guo Y. LaFrance-Corey R.G. Gamez J.D. Atanga P.A. Clarkson B.D. Zhang Y. Wang E. Angom R.S. Dutta K. Ji B. Pirko I. Lucchinetti C.F. Howe C.L. Mukhopadhyay D. Neuropilin-1 modulates interferon-γ-stimulated signaling in brain microvascular endothelial cells. J. Cell Sci. 2016 129 20 3911 3921 10.1242/jcs.190702 27591257
220 Burks S.M. Rosas-Hernandez H. Ramirez-Lee A.M. Cuevas E. Talpos J.C. Can SARS-CoV-2 infect the central nervous system via the olfactory bulb or the blood-brain barrier? Brain Behav. Immun. 2021 95 7 14 10.1016/j.bbi.2020.12.031 33412255
221 Atlas, H.P. The human protein atlas. 2021 https://www.proteinatlas.org/
222 Cabirac G.F. Murray R.S. McLaughlin L.B. Skolnick D.M. Hogue B. Dorovini-Zis K. Didier P.J. In vitro interaction of coronaviruses with primate and human brain microvascular endothelial cells. Adv. Exp. Med. Biol. 1995 380 79 88 10.1007/978-1-4615-1899-0_11 8830550
223 Nuovo G.J. Magro C. Shaffer T. Awad H. Suster D. Mikhail S. He B. Michaille J.J. Liechty B. Tili E. Endothelial cell damage is the central part of COVID-19 and a mouse model induced by injection of the S1 subunit of the spike protein. Ann. Diagn. Pathol. 2021 51 151682 10.1016/j.anndiagpath.2020.151682 33360731
224 Reynolds J.L. Mahajan S.D. SARS-COV2 alters blood brain barrier integrity contributing to neuro-inflammation. J. Neuroimmune Pharmacol. 2021 16 1 4 6 10.1007/s11481-020-09975-y 33405097
225 Varga Z. Flammer A.J. Steiger P. Haberecker M. Andermatt R. Zinkernagel A.S. Mehra M.R. Schuepbach R.A. Ruschitzka F. Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020 395 10234 1417 1418 10.1016/S0140-6736(20)30937-5 32325026
226 Buzhdygan T.P. DeOre B.J. Baldwin-Leclair A. Bullock T.A. McGary H.M. Khan J.A. Razmpour R. Hale J.F. Galie P.A. Potula R. Andrews A.M. Ramirez S.H. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier. Neurobiol. Dis. 2020 146 105131 10.1016/j.nbd.2020.105131 33053430
227 Al-Harthi L. Campbell E. Schneider J.A. Bennett D.A. What HIV in the brain can teach us about SARS-CoV-2 neurological complications? AIDS Res. Hum. Retroviruses 2021 37 4 255 265 10.1089/aid.2020.0161 32683890
228 Edwards J.A. Denis F. Talbot P.J. Activation of glial cells by human coronavirus OC43 infection. J. Neuroimmunol. 2000 108 1-2 73 81 10.1016/S0165-5728(00)00266-6 10900340
229 Paniz-Mondolfi A. Bryce C. Grimes Z. Gordon R.E. Reidy J. Lednicky J. Sordillo E.M. Fowkes M. Central nervous system involvement by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). J. Med. Virol. 2020 92 7 699 702 10.1002/jmv.25915 32314810
230 Sardu C. Gambardella J. Morelli M.B. Wang X. Marfella R. Santulli G. Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? a comprehensive evaluation of clinical and basic evidence. J. Clin. Med. 2020 9 5 1417 10.3390/jcm9051417 32403217
231 Stewart J.N. Mounir S. Talbot P.J. Human coronavirus gene expression in the brains of multiple sclerosis patients. Virology 1992 191 1 502 505 10.1016/0042-6822(92)90220-J 1413524
232 Antinori A. Arendt G. Becker J.T. Brew B.J. Byrd D.A. Cherner M. Clifford D.B. Cinque P. Epstein L.G. Goodkin K. Gisslen M. Grant I. Heaton R.K. Joseph J. Marder K. Marra C.M. McArthur J.C. Nunn M. Price R.W. Pulliam L. Robertson K.R. Sacktor N. Valcour V. Wojna V.E. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007 69 18 1789 1799 10.1212/01.WNL.0000287431.88658.8b 17914061
233 McArthur J.C. Brew B.J. HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS 2010 24 9 1367 1370 10.1097/QAD.0b013e3283391d56 20559041
234 McFarren A. Lopez L. Williams D.W. Veenstra M. Bryan R.A. Goldsmith A. Morgenstern A. Bruchertseifer F. Zolla-Pazner S. Gorny M.K. Eugenin E.A. Berman J.W. Dadachova E. A fully human antibody to gp41 selectively eliminates HIV-infected cells that transmigrated across a model human blood brain barrier. AIDS 2016 30 4 563 572 10.1097/QAD.0000000000000968 26595540
235 Persidsky Y. Hill J. Zhang M. Dykstra H. Winfield M. Reichenbach N.L. Potula R. Mukherjee A. Ramirez S.H. Rom S. Dysfunction of brain pericytes in chronic neuroinflammation. J. Cereb. Blood Flow Metab. 2016 36 4 794 807 10.1177/0271678X15606149 26661157
236 Persidsky Y. Zheng J. Miller D. Gendelman H.E. Mononuclear phagocytes mediate blood-brain barrier compromise and neuronal injury during HIV-1-associated dementia. J. Leukoc. Biol. 2000 68 3 413 422 10.1189/jlb.68.3.413 10985259
237 Solomon T. Patabendige A. Whitley R.J. Arthropod-borne viral encephalititdes. Infections of the central nervous system Scheld WMW, J, R. Marra C.M. Philadelphia, PA, USA Lippincott Williams & Wilkins 2014 210 238
238 Verma S. Lo Y. Chapagain M. Lum S. Kumar M. Gurjav U. Luo H. Nakatsuka A. Nerurkar V.R. West Nile virus infection modulates human brain microvascular endothelial cells tight junction proteins and cell adhesion molecules: Transmigration across the in vitro blood-brain barrier. Virology 2009 385 2 425 433 10.1016/j.virol.2008.11.047 19135695
239 Velandia-Romero M.L. Calderón-Peláez M.A. Castellanos J.E. In vitro infection with dengue virus induces changes in the structure and function of the mouse brain endothelium. PLoS One 2016 11 6 e0157786 10.1371/journal.pone.0157786 27336851
240 Turtle L. Griffiths M.J. Solomon T. Encephalitis caused by flaviviruses. QJM 2012 105 3 219 223 10.1093/qjmed/hcs013 22367423
241 da Silva I.R.F. Frontera J.A. de Filippis B.A.M. Nascimento O.J.M. Neurologic complications associated with the Zika virus in Brazilian adults. JAMA Neurol. 2017 74 10 1190 1198 10.1001/jamaneurol.2017.1703 28806453
242 Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002 36 5 S21 S29 12407573
243 Farquhar M.J. McKeating J.A. Primary hepatocytes as targets for Hepatitis C virus replication. J. Viral Hepat. 2008 15 12 849 854 10.1111/j.1365-2893.2008.01051.x 19087224
244 Ploss A. Evans M.J. Gaysinskaya V.A. Panis M. You H. de Jong Y.P. Rice C.M. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009 457 7231 882 886 10.1038/nature07684 19182773
245 Fletcher N.F. Wilson G.K. Murray J. Hu K. Lewis A. Reynolds G.M. Stamataki Z. Meredith L.W. Rowe I.A. Luo G. Lopez-Ramirez M.A. Baumert T.F. Weksler B. Couraud P.O. Kim K.S. Romero I.A. Jopling C. Morgello S. Balfe P. McKeating J.A. Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology 2012 142 3 634 643.e6 10.1053/j.gastro.2011.11.028 22138189
246 Untucht C. Rasch J. Fuchs E. Rohde M. Bergmann S. Steinert M. An optimized in vitro blood-brain barrier model reveals bidirectional transmigration of African trypanosome strains. Microbiology 2011 157 10 2933 2941 10.1099/mic.0.049106-0 21737496
247 Howland S.W. Poh C.M. Rénia L. Activated brain endothelial eells cross- present malaria antigen. PLoS Pathog. 2015 11 6 e1004963 10.1371/journal.ppat.1004963 26046849
248 Zougbédé S. Miller F. Ravassard P. Rebollo A. Cicéron L. Couraud P.O. Mazier D. Moreno A. Metabolic acidosis induced by Plasmodium falciparum intraerythrocytic stages alters blood-brain barrier integrity. J. Cereb. Blood Flow Metab. 2011 31 2 514 526 10.1038/jcbfm.2010.121 20683453
249 Lachenmaier S.M. Deli M.A. Meissner M. Liesenfeld O. Intracellular transport of toxoplasma gondii through the blood-brain barrier. J. Neuroimmunol. 2011 232 1-2 119 130 10.1016/j.jneuroim.2010.10.029 21106256
250 Kanmogne G.D. Schall K. Leibhart J. Knipe B. Gendelman H.E. Persidsky Y. HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: Implication for viral neuropathogenesis. J. Cereb. Blood Flow Metab. 2007 27 1 123 134 10.1038/sj.jcbfm.9600330 16685256
251 Mahajan S.D. Aalinkeel R. Sykes D.E. Reynolds J.L. Bindukumar B. Adal A. Qi M. Toh J. Xu G. Prasad P.N. Schwartz S.A. Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: Implication for HIV-1 neuropathogenesis in the context of drug abuse. Brain Res. 2008 1203 133 148 10.1016/j.brainres.2008.01.093 18329007
252 Persidsky Y. Stins M. Way D. Witte M.H. Weinand M. Kim K.S. Bock P. Gendelman H.E. Fiala M. A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J. Immunol. 1997 158 7 3499 3510 10.4049/jimmunol.158.7.3499 9120312
253 Rochfort K.D. Cummins P.M. In vitro cell models of the human blood-brain barrier: Demonstrating the beneficial influence of shear stress on brain microvascular endothelial cell phenotype. Blood-Brain Barrier. Barichello T. New York, NY Springer New York 2019 71 98 10.1007/978-1-4939-8946-1_5
254 Perel P. Roberts I. Sena E. Wheble P. Briscoe C. Sandercock P. Macleod M. Mignini L.E. Jayaram P. Khan K.S. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 2007 334 7586 197 200 10.1136/bmj.39048.407928.BE 17175568
255 Wasielewska J.M. Da J.C. Chaves S. White A.R. Oikari L.E. To understand drug delivery in Alzheimer’s disease. Alzheimer’s disease: drug discovery Huang X. Exon Publications Brisbane (AU) 2020 117 134 10.36255/exonpublications.alzheimersdisease.2020.ch7
256 Brown J.A. Faley S.L. Shi Y. Hillgren K.M. Sawada G.A. Baker T.K. Wikswo J.P. Lippmann E.S. Advances in blood-brain barrier modeling in microphysiological systems highlight critical differences in opioid transport due to cortisol exposure. Fluids Barriers CNS 2020 17 1 38 10.1186/s12987-020-00200-9 32493346
257 Summerfield S.G. Lucas A.J. Porter R.A. Jeffrey P. Gunn R.N. Read K.R. Stevens A.J. Metcalf A.C. Osuna M.C. Kilford P.J. Passchier J. Ruffo A.D. Toward an improved prediction of human in vivo brain penetration. Xenobiotica 2008 38 12 1518 1535 10.1080/00498250802499459 18979396
258 Lacombe O. Videau O. Chevillon D. Guyot A.C. Contreras C. Blondel S. Nicolas L. Ghettas A. Bénech H. Thevenot E. Pruvost A. Bolze S. Krzaczkowski L. Prévost C. Mabondzo A. In vitro primary human and animal cell-based blood-brain barrier models as a screening tool in drug discovery. Mol. Pharm. 2011 8 3 651 663 10.1021/mp1004614 21438632
259 Drummond E. Wisniewski T. Alzheimer’s disease: Experimental models and reality. Acta Neuropathol. 2017 133 2 155 175 10.1007/s00401-016-1662-x 28025715
260 Breschi A. Gingeras T.R. Guigó R. Comparative transcriptomics in human and mouse. Nat. Rev. Genet. 2017 18 7 425 440 10.1038/nrg.2017.19 28479595
261 Nguyen T.V.V. Frye J.B. Zbesko J.C. Stepanovic K. Hayes M. Urzua A. Serrano G. Beach T.G. Doyle K.P. Multiplex immunoassay characterization and species comparison of inflammation in acute and non-acute ischemic infarcts in human and mouse brain tissue. Acta Neuropathol. Commun. 2016 4 1 100 10.1186/s40478-016-0371-y 27600707
262 Wang M.M. Zhang X. Lee S.J. Maripudi S. Keep R.F. Johnson A.M. Stamatovic S.M. Andjelkovic A.V. Expression of periaxin (PRX) specifically in the human cerebrovascular system: PDZ domain-mediated strengthening of endothelial barrier function. Sci. Rep. 2018 8 1 10042 10.1038/s41598-018-28190-7 29968755
263 Urich E. Lazic S.E. Molnos J. Wells I. Freskgård P.O. Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models. PLoS One 2012 7 5 e38149 10.1371/journal.pone.0038149 22675443
264 Hoshi Y. Uchida Y. Tachikawa M. Inoue T. Ohtsuki S. Terasaki T. Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. J. Pharm. Sci. 2013 102 9 3343 3355 10.1002/jps.23575 23650139
265 O’Brown N.M. Pfau S.J. Gu C. Bridging barriers: A comparative look at the blood-brain barrier across organisms. Genes Dev. 2018 32 7-8 466 478 10.1101/gad.309823.117 29692355
266 Oberheim N.A. Wang X. Goldman S. Nedergaard M. Astrocytic complexity distinguishes the human brain. Trends Neurosci. 2006 29 10 547 553 10.1016/j.tins.2006.08.004 16938356
267 Prashanth A. Donaghy H. Stoner S.P. Hudson A.L. Wheeler H.R. Diakos C.I. Howell V.M. Grau G.E. McKelvey K.J. Are in vitro human blood-brain-tumor‐barriers suitable replacements for in vivo models of brain permeability for novel therapeutics? Cancers 2021 13 5 955 10.3390/cancers13050955 33668807
268 Ito R. Umehara K. Suzuki S. Kitamura K. Nunoya K. Yamaura Y. Imawaka H. Izumi S. Wakayama N. Komori T. Anzai N. Akita H. Furihata T. A human immortalized cell-based blood-brain barrier triculture model: Development and characterization as a promising tool for drug-brain permeability studies. Mol. Pharm. 2019 16 11 4461 4471 10.1021/acs.molpharmaceut.9b00519 31573814
269 Cioni C. Turlizzi E. Zanelli U. Oliveri G. Annunziata P. Expression of tight junction and drug efflux transporter proteins in an in vitro model of human blood-brain barrier. Front. Psychiatry 2012 3 47 10.3389/fpsyt.2012.00047 22593745
